[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-adult-participants\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-adult-participants":34},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,63,0,25,[9,56,90,118,145,166,198,226,256,282,303,335,365,394,416,437,456,482,512,538,566,586,612,632,653],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":22,"targetDuration":4,"studyType":25,"phases":26,"briefSummary":28,"conditions":29,"keywords":35,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100652602","satiety-microbiome-appetite-regulation-and-tracking-energy-across-targeted-snacks-acute-postprandial-study-100652602",false,"NCT07776418","Satiety, Microbiome, Appetite Regulation, and Tracking Energy Across Targeted Snacks: Acute Postprandial Study","The ZOE SMART EATS (Satiety, Microbiome, Appetite Regulation, and Tracking Energy Across Targeted Snacks) Acute Postprandial Study: Investigating the Acute Effects of a High-fibre Plant-based Snack Bar on Subjective Postprandial Hunger, Energy Intake and Eating Behaviour in Healthy UK Adults.","SMARTEATS-PP","Inclusion Criteria:\n\n* Willing and able to follow the study protocol\n* Willing and able to provide informed consent\n* Regular consumption of snacks (≥2 per day)\n* Fibre intake \\\u003C20 g\u002Fd\n* Living in the UK\n\nExclusion Criteria:\n\n* Have BMI of less than 18.5 kg\u002Fm² or more than 40 kg\u002Fm²\n* Have an allergy or intolerance to ingredients in the intervention or control snack bars (including inulin) or cannot eat the food products safely and comfortably for any reason\n* Have a personal medical history of inflammatory bowel disease, coeliac disease, Crohn's disease, irritable bowel syndrome, chronic constipation, or chronic diarrhoea\n* Have started a new supplement in the past month, or are unwilling to maintain current supplement use throughout the study\n* Previously purchased any ZOE products (including Daily30, ZOE gut health bar or ZOE app membership).\n* Have taken any medication or product that may modify the measured study outcomes, in the past 3 months (including but not limited to: fibre supplements, antibiotics, non-topical steroids or other immunosuppressive medicines, probiotics or prebiotics, metformin, GLP-1 receptor agonists, lipid-lowering medications such as fibrates, statins, PCSK9 inhibitors, non-steroidal anti-inflammatory drugs)\n* Have used opiate pain medication or a proton pump inhibitor for 8 or more consecutive days during the past 3 months\n* Have experienced a heart attack, stroke or major surgery in the last 2 months\n* Have received treatment for cancer in the last 3 months\n* Are currently pregnant, breastfeeding or planning a pregnancy\n* Are diagnosed with an eating disorder, type 1 diabetes mellitus or type 2 diabetes mellitus",true,"ALL","35 Years","65 Years",{"count":23,"type":24},54,"ESTIMATED","INTERVENTIONAL",[27],"NA","The goal of this clinical trial is to learn how eating different snack foods affects acute hunger, energy intake and eating behaviour in healthy adults. The study will be conducted remotely over 5 days.\n\nThe main questions it aims to answer are:\n\n1. Does eating a snack bar intervention change how hungry participants feel later in the same day?\n2. Does eating a snack bar intervention change participants' energy intake, nutrient intake and eating behaviour on the same day?\n3. Does eating a snack bar intervention change participants mood, energy levels and alertness later in the same day?\n\nResearchers will compare an intervention snack bar to a control snack bar to see if the intervention improves hunger, energy intake, eating behaviour, and other subjective measures.\n\nParticipants will:\n\n* Eat 2 snack bars for breakfast on 2 separate days, with 2 days in between\n* Not eat anything after 9pm the night before each test day\n* Fill out short online surveys (under 5 minutes) before breakfast and at set times over the next 3 hours\n* Not eat for 3 hours after breakfast\n* Write down everything they eat that day",[30,31,32,33,34],"Healthy Participants","Healthy Adult Subject","Healthy Subjects","Healthy Adult Volunteer","Healthy Adult Participants",[36,37,38,39,40,41,42],"Snacks","Snack foods","Dietary intervention","Hunger","Health","Wellbeing","Nutrition study","NOT_YET_RECRUITING","2026-08-19",{"date":46,"type":47},"2026-08-20","ACTUAL",{"date":49,"type":24},"2026-08-14",{"date":51,"type":24},"2026-10",{"name":53,"class":54},"Zoe Global Limited","OTHER",1,{"id":57,"slug":58,"hasResults":12,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":18,"sex":19,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":25,"phases":67,"briefSummary":69,"conditions":70,"keywords":74,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":55},"100652893","phase-1-alpelisib-challenge-test-act-100652893","NCT07778524","Alpelisib Challenge Test (ACT)","Alpelisib Challenge Test (ACT) for Assessment of Pancreatic β-Cell Reserve, Pilot & Feasibility Study","Inclusion Criteria:\n\n* Adults aged 18-70 years\n* Able to understand wrifen and spoken English and\u002For Spanish\n* Body mass index of 18-45 kg\u002Fm2 (or 18-42 kg\u002Fm2 for those of Asian ancestry)\n\n  * For Lean group: BMI 18.0-24.9 kg\u002Fm2 (or 18.0-22.9 kg\u002Fm2 for those of Asian ancestry)\n  * For Overweight group: BMI 25.0-29.9 kg\u002Fm2 (or 23.0-27.4 kg\u002Fm2 for those of Asian ancestry)\n  * For Obesity group: BMI 30.0-45.0 kg\u002Fm2 (or 27.5-42 kg\u002Fm2 for those of Asian ancestry)\n\nExclusion Criteria:\n\n* Inability to provide informed consent in English or Spanish\n* Unwillingness to fast (except water) for up to 18 hours\n* Unwillingness not to get out of bed and to use bedpan\u002Furinal to void for up to 15 hours\n* Documented weight change of ≥ 5.0% of baseline within the previous 3 months\n* Abnormal blood pressure\n\n  * Systolic blood pressure \\\u003C 90 mm Hg or \\> 160 mm Hg, and\u002For\n  * Diastolic blood pressure \\\u003C 55 mm Hg or \\> 100 mm Hg\n* Abnormal resting heart rate \\\u003C 55 bpm or ≥ 110 bpm\n\n  * Sinus tachycardia that has been extensively worked up and considered benign by the recruit's personal physician may be permitted at the PI's discretion\n  * Sinus bradycardia between heart rates of 45 and 54 bpm may be permitted at the PI's discretion if in a clinically appropriate setting (e.g., toned athlete, taking beta blockers)\n* Abnormal (i.e., non-regular) heart rhythm detected on physical exam\n* Abnormal screening serum electrolytes judged by the PI to be potentially clinically significant\n* Liver function abnormalities (either of the following)\n\n  * Transaminases (AST or ALT) \\> 3.0 x the upper limit of normal\n  * Total bilirubin \\> 1.25 x the upper limit of normal\n* Laboratory evidence of diabetes mellitus:\n\n  * Hemoglobin A1c ≥ 6.5%, and\u002For\n  * Fasting plasma glucose ≥ 126 mg dL-1\n* Positive qualitative β-hCG (i.e., pregnancy test) in women of childbearing potential\n* Women currently pregnant\n* Women currently breastfeeding\n* History of having met any of the American Diabetes Association's definitions of diabetes mellitus (i.e., overt diabetes):\n\n  * Hemoglobin A1c ≥ 6.5%, or rapid rise in documented HbA1c values causing clinical concern for evolving insulin deficiency\n  * Plasma glucose ≥ 126 mg\u002FdL after 8-h fast\n  * Plasma glucose of ≥ 200 mg\u002FdL at 2 h after ingestion of a 75-g glucose load\n  * Random plasma glucose ≥ 200 mg\u002FdL associated with typical hyperglycemic symptoms, diabetic ketoacidosis, or hyperglycemic-hyperosmolar state\n* History of gestational diabetes mellitus within the previous 5 years\n* Use of most antidiabetic medications within the 90 days prior to screening\n\n  * Exceptions: thiazolidinediones, sulfonylureas, meglitinides, DPP4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, amylin mimetics, acarbose, insulin\n  * Metformin is acceptable provided that recruits meet all of the inclusion criteria at screening\n* Clinical concern for absolute insulin deficiency (e.g., type 1 diabetes, pancreatic disease)\n* Cardiovascular diseases (N.B. uncomplicated hypertension is not exclusionary)\n\n  * Atherosclerotic cardiovascular disease\n  * Stable or unstable angina\n  * Myocardial infarction\n  * Ischaemic or hemorrhagic stroke\n  * Peripheral arterial disease (claudication)\n  * Use of dual antiplatelet therapy (aspirin + P2Y12 inhibitor)\n  * History of percutaneous coronary intervention\n  * Congestive heart failure (NYHA Class ≥ 2)\n  * Severe valvular heart disease (e.g., aortic stenosis)\n  * Pulmonary hypertension\n* Advanced or severe liver disease, including but not limited to:\n\n  * Advanced liver fibrosis, as determined by non-invasive testing\n  * Cirrhosis of any etiology\n  * Autoimmune hepatitis or other rheumatologic disorder affecting the liver\n  * Biliopathy (e.g., progressive sclerosing cholangitis, primary biliary cholangitis)\n  * Chronic liver infection (e.g., viral hepatitis, parasitic infestation)\n  * Hepatocellular carcinoma\n  * Infiltrative disorders (e.g., sarcoidosis, hemochromatosis, Wilson disease)\n* Psychiatric diseases causing functional impairment that:\n\n  * Are or have been decompensated within 1 year of screening, and\u002For\n  * Require use of anti-dopaminergic antipsychotic drugs associated with significant weight gain\u002Fmetabolic dysfunction (e.g., clozapine, olanzapine)\n* Venous thromboembolic disease (deep vein thrombosis or pulmonary embolism) or any required use of therapeutic anticoagulation\n* Bleeding disorders, including due to anticoagulation, or significant anemia (see above)\n* Active malignancy, or hormonally active benign neoplasm, except allowances for:\n\n  * Non-melanoma skin cancer\n  * Differentiated thyroid cancer (AJCC Stage I only)\n* Clinical concern for increased risk of volume overload, including due to medications and\u002For heart\u002Fliver\u002Fkidney problems, as listed above\n* Use of certain medications currently or within 30 days prior to screening:\n\n  * Prescribed medications used for any of the indications in the preceding list of excluded conditions, or their use within 30 d prior to screening, except allowances for:\n\n    * Use of drugs prescribed for indications other than the exclusionary diagnoses\u002Fpurposes listed above (e.g., ACEi\u002FARB used for uncomplicated hypertension rather than for congestive heart failure, etc.)\n    * Note, as above, that antidiabetic drugs except metformin within 30 d of screening are excluded\n  * Oral or parenteral corticosteroids (at greater than prednisone 5 mg daily, or equivalent) for more than 3 days within the previous 30 days; topical and inhaled formulations are permitted\n* History of certain weight-loss (bariatric) surgery, including:\n\n  * Roux-en-Y gastric bypass\n  * Biliopancreatic diversion\n  * Restrictive procedures (lap band, sleeve gastrectomy) performed within the past 6 months\n* Clinical concern for alcohol overuse based on chart review and\u002For by recruit's report of more than 14 standard drinks per week for males or more than 7 standard drinks per week for females\n* Regular tobacco use (smoking more than 1 cigarette per week) or regular nicotine vaping (daily)\n* Clinical concern for use of illicit drugs other than marijuana or lawfully prescribed medications based on recruit's report, chart review, and point-of-care urine drug test at screening\n* History of or ongoing febrile illness within 14 days of screening\n* Any other disease or condition or laboratory value that, in the opinion of the investigator, would place the participant at an unacceptable risk and\u002For interfere with the analysis of study data.\n* Known allergy\u002Fhypersensitivity to any component of the medicinal product formulations (including soy, cow dairy, or gluten), other biologics, venipuncture materials, plastics, adhesive or silicone, or ongoing clinically important allergy\u002Fhypersensitivity as judged by the investigator.\n* Concurrent enrollment in another clinical study of any investigational drug\u002Fbiologic therapy within 5 half-lives of an investigational agent or biologic.","18 Years","70 Years",{"count":66,"type":24},15,[68],"PHASE1","The goal of this study is to test a potentially easier method for measuring how much insulin a person is capable of producing than the current gold-standard method, the \"hyperglycemic clamp.\" Participants will come in for a two-day (overnight) visit in which they will first undergo a \"hyperglycemic clamp,\" in which they receive an intravenous (into the vein) infusion of glucose (sugar) in order to measure the maximum amount of insulin their body produces in response. They will then consume a series of three standardized meals throughout the rest of the day. At 23:00, they will take a single dose of alpelisib, a drug that interferes within insulin's actions in the body. Then, the following morning, they will undergo a \"Mixed Meal Tolerance Test\" in which they consume a standardized liquid nutritional beverage and have blood drawn periodically before and during the test.",[71,72,73,34],"Insulin Resistance","Type 2 Diabetes","Obesity & Overweight",[75,76,77,78,79,80],"Insulin resistance","Type 2 diabetes","Hyperinsulinemia","Obesity","Overweight","Healthy volunteers","2026-08-18",{"date":83,"type":47},"2026-08-21",{"date":85,"type":24},"2026-09-01",{"date":87,"type":24},"2028-08-31",{"name":89,"class":54},"Columbia University",{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":18,"sex":19,"minAge":63,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":25,"phases":100,"briefSummary":101,"conditions":102,"keywords":105,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":111,"startDateStruct":112,"completionDateStruct":113,"leadSponsor":115,"locationsCount":4},"100652849","stimulation-evaluation-for-neuromodulation-sensory-effects-100652849","NCT07777991","Stimulation Evaluation for Neuromodulation Sensory Effects","SENSE","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Self-reported good general health, as assessed by study personnel.\n\nExclusion Criteria:\n\n1. Non-English speaking\n2. History of epilepsy, seizure disorder, unprovoked seizure, or status epilepticus.\n3. History of febrile seizures beyond early childhood\n4. Current use of medications known to substantially lower seizure threshold, including but not limited to certain antidepressants, antipsychotics, stimulants,\n5. History of significant neurological disease, including stroke, traumatic brain injury with loss of consciousness, brain tumor, neurodegenerative disease, multiple sclerosis, or other clinically significant neurological disorders.\n6. Prior intracranial neurosurgical procedure or implanted neurostimulation device.\n7. Presence of an implanted electrical, neurostimulation, cardiac rhythm management, or other active implanted medical device.\n8. Significant scalp abnormalities that may interfere with electrode placement, including active skin disease, open wounds, infection, or severe dermatologic conditions involving the scalp.\n9. Current diagnosis of a major psychiatric disorder that, in the opinion of the investigator, may interfere with study participation or interpretation of study results.\n10. History of severe depression associated with suicidal ideation, suicidal behavior, suicide attempt, psychiatric hospitalization for suicidality.\n11. Current suicidal ideation or behavior, as determined by participant self-report.\n12. Current substance abuse and\u002For alcohol dependence that may impair the participant's ability to safely complete study procedures.\n13. Pregnant or breastfeeding.\n14. Participation in another investigational drug, biologic, or device study within 30 days prior to enrollment, unless approved by the investigator and sponsor.\n15. History of migraine with aura, photosensitive migraine, recurrent phosphenes, visually induced neurological symptoms, or other conditions associated with heightened susceptibility to visual sensory phenomena, as determined by the investigator.\n16. History of recurrent syncope, unexplained loss of consciousness, vasovagal episodes requiring medical intervention, or other conditions associated with increased risk of fainting during medical procedures or sensory stimulation, as determined by the investigator.","85 Years",{"count":99,"type":24},30,[27],"The goal of this clinical trial is to learn how healthy adults experience low-level electrical stimulation delivered through the study device. This study is not intended to treat a medical condition.\n\nThe main questions it aims to answer are:\n\nIs the study stimulation comfortable and well tolerated? What sensations do participants notice during stimulation? Can participants tell the difference between active stimulation and sham stimulation?\n\nResearchers will compare active stimulation with sham stimulation. Sham stimulation uses the same study procedures but does not deliver the study stimulation. This comparison will help researchers understand whether sensations are caused by stimulation rather than the study setting or expectations.\n\nParticipants will:\n\nReceive brief sessions of active and sham stimulation using the study device. Report sensations, discomfort, or other effects during and after each session. Complete questionnaires or other assessments about their experience with stimulation.\n\nThe information from this study will help researchers select stimulation settings and procedures for future studies.",[103,34,104],"Sham-controlled","Electric Stimulation",[80,106,107,108,109,103,110],"Electrical stimulation","Intersectional Short-Pulse (ISP) stimulation","Neuromodulation","Sensory effects","Noninvasive brain stimulation",{"date":83,"type":47},{"date":85,"type":24},{"date":114,"type":24},"2027-09-01",{"name":116,"class":117},"Adraxe Corp.","INDUSTRY",{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":18,"sex":19,"minAge":63,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":25,"phases":127,"briefSummary":129,"conditions":130,"keywords":131,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":138,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":55},"100628138","early-phase-1-evaluation-of-18fgatt-44-for-positron-emission-tomography-imaging-of-the-gaba-transporter-1-100628138","NCT07457736","Evaluation of [18F]GATT-44 for Positron Emission Tomography Imaging of the GABA Transporter-1","Inclusion Criteria:\n\n1. Willing and able to give voluntary written informed consent;\n2. Able to read and write, able to communicate effectively with the investigator, and comply with all study requirements, restrictions, and directions of the research staff;\n3. Male or female, aged 18 to 60, at screening;\n4. In good general health as evidenced by medical history, physical examination, ECG, serum\u002Furine biochemistry, hematology, and serology tests;\n5. Females of childbearing potential, and male subjects, must be willing to practice birth control for the duration of the study (unless medical documentation is provided confirming subject is permanently sterile).\n\nExclusion:\n\n1. Less than 18 years of age;\n2. Pregnant or breastfeeding;\n3. Any significant systemic illness or unstable medical condition;\n4. Pre-existing medical conditions or claustrophobic reactions;\n5. Research-related radiation exposure exceeds current PET Center guidelines;\n6. History of a bleeding disorder or are currently taking anticoagulants.","60 Years",{"count":126,"type":24},32,[128],"EARLY_PHASE1","Evaluate \\[18F\\]GATT-44 (aka \\[18F\\]GAT44), to characterize its pharmacokinetic, metabolic, and in vivo binding profile, and assess the reproducibility of kinetic and binding parameters. Assess specific binding levels of \\[18F\\]GATT-44 by conducting a test-block study in humans. Estimate human dosimetry of \\[18F\\]GATT-44 by performing whole-body imaging studies.",[34],[132,133,134,135,136],"gatt44","experimental radiotracer","first in human radiotracer","GAT-1","GATT-44","RECRUITING",{"date":46,"type":47},{"date":140,"type":47},"2026-01-28",{"date":142,"type":24},"2030-01",{"name":144,"class":54},"Yale University",{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":18,"sex":19,"minAge":63,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":155,"phases":4,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":4},"100644272","global-reference-ranges---mexico-100644272","NCT07664982","Global Reference Ranges - Mexico","Global Reference Ranges (GRR) for Magnetic Resonance Imaging of Intra-abdominal Organs in Healthy Adults From Different Ethnic Groups - Mexico","GRR Mexico","Inclusion Criteria:\n\n* Male or female at least 18 years of age\n* Self-reported healthy\n* Willing and able to give informed consent for participation in the study\n* Willing and able to undergo an MRI\n\nExclusion Criteria:\n\n* History of cardiovascular disease as follows:\n\n  * Myocardial infarction\n  * Heart failure\n  * Cardiomyopathy\n  * Stroke\n  * Hospital admission\u002Fdischarge for unstable angina\n  * Heart surgery\n  * Unstable angina\n  * Transient ischemic attack\n* Presence of CVD risk factors such as hypertension, hyperlipidaemia, Type 2 diabetes, BMI \\> 30 kg\u002Fm2, smoker (current\u002Fex-smoker)\n* History of non-cardiac diseases related to the lungs, liver, kidneys, pancreas or spleen judged by the study investigator as therefore unsuitable to participate in the study\n* The participant may not enter the study if they have any contraindication to magnetic resonance imaging (standard MRI exclusion criteria including pregnancy, extensive tattoos, pacemaker, shrapnel injury, severe claustrophobia)\n* Any other cause, including a significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the participant's ability to participate in the study",{"count":154,"type":24},50,"OBSERVATIONAL","The investigators aim to undertake the Global Reference Range Study (GRR) to establish a set of healthy adult reference values for measures of fibroinflammation, fat and size\u002Fvolumes for the liver, and other abdominal and thoracic organs to assess, compare, and if necessary, propose ethnicity specific reference ranges for these measurements.",[34],"2026-08-17",{"date":44,"type":47},{"date":161,"type":24},"2026-08",{"date":163,"type":24},"2029-08",{"name":165,"class":117},"Perspectum",{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":18,"sex":19,"minAge":63,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":155,"phases":4,"briefSummary":174,"conditions":175,"keywords":176,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":193,"leadSponsor":195,"locationsCount":197},"100652737","observational-study-of-decentralized-urine-optical-interaction-patterns-associated-with-environmental-microplastic-and-nanoplastic-exposure-100652737","NCT07775495","Observational Study of Decentralized Urine Optical Interaction Patterns Associated With Environmental Microplastic and Nanoplastic Exposure","OMNU","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Able to provide electronic informed consent\n* Willing and able to collect and prepare urine samples at home according to study instructions\n* Own a smartphone capable of running the TrialKit application and capturing photographs\n* Willing to complete the required study visits over approximately 12 weeks\n\nExclusion Criteria:\n\n* Unable or unwilling to perform the study procedures (urine collection, sample preparation, smartphone imaging, and data upload)\n* Any condition or circumstance that, in the judgment of the investigator, would prevent the participant from successfully completing the study protocol",{"count":66,"type":24},"The goal of this observational study is to evaluate the feasibility and usability of at-home urine sample collection, preparation, and smartphone imaging using the EcoExposure™ platform in adults. The main questions it aims to answer are:\n\nCan participants successfully collect, prepare, and photograph urine samples at home and upload the images using a smartphone app? How consistent is image quality and participant adherence across repeated sampling over approximately 12 weeks? What is the short-term day-to-day variability in optical signals during an intensive daily sampling period?\n\nParticipants will:\n\nComplete electronic consent and a brief intake questionnaire Collect and prepare urine samples at home at scheduled timepoints Capture guided smartphone photographs of the prepared samples Upload the images and provide brief feedback through the TrialKit app Optionally add a small reference solution (spike sample) to one sample for technical evaluation only\n\nThe study is fully remote and lasts approximately 12 weeks. It is intended for product development and workflow validation purposes only and does not involve any diagnostic or clinical decision-making.",[34],[177,178,179,180,181,182,183,184,185,186,187,188,189],"environmental","environmental health","environmental exposure","microplastics","nanoplastics","urine","smartphone","feasibility","usability","at-home","decentratlized","observational","optical analysis","2026-08-16",{"date":46,"type":47},{"date":83,"type":24},{"date":194,"type":24},"2027-01-31",{"name":196,"class":117},"Ecotera Health LLC",51,{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":18,"sex":19,"minAge":63,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":155,"phases":4,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":4},"100650624","brain-dopamine-biomarker-100650624","NCT07748715","Brain Dopamine Biomarker","Blue Color Processing in the Eye as a Biomarker of Brain Dopamine","B3-4D","Inclusion Criteria:\n\n* Parkinson's subjects will have received physician verified diagnosis of the disease and be on a dopaminergic medication for at least 3 months\n\nExclusion Criteria:\n\n* Any movement, strength, or balance assessments that may pose a potential risk for injury\n* Individuals with a history of photosensitive epilepsy or seizure activity triggered by visual stimuli\n* Current use of antipsychotics, stimulants, or other medications known to affect central dopaminergic transmission\n* Pregnancy\n* Recent ocular surgery\n* Phenylketonuria\n* (PD participants) not cognitively intact and not able to consent for themselves\n* (non-PD subjects) a pre-screening survey will assess medication use and neurological history\n* Ophthalmologic or visual system conditions that may interfere with stimulus delivery or retinal function. These include significant cataract (defined as LOCS III ≥ NC2\u002FNO2 or any media opacity that precludes adequate delivery of visual stimuli to the retina), active retinal or macular pathology (including age-related macular degeneration with significant drusen or geographic atrophy, diabetic retinopathy, retinal vein occlusion, or epiretinal membrane with foveal involvement), glaucoma, or any optic neuropathy.\n* Individuals with congenital color vision deficiencies, particularly tritan-spectrum defects\n* Ocular surgery within the past three months\n* Use of medications known to affect retinal electrophysiology (e.g., chronic hydroxychloroquine, vigabatrin, deferoxamine, or isotretinoin)\n* History of photosensitive epilepsy or visually triggered seizures (especially relevant given the use of bright visual stimuli and potential flicker paradigms)",{"count":154,"type":24},"This study is being conducted at the Morsani College of Medicine to determine whether signals recorded from the eyes and brain can be used as a noninvasive way to monitor dopamine function. Approximately 50 adults (25 with Parkinson's disease and 25 without Parkinson's disease) will participate. Participants will undergo electroretinography (ERG) and electroencephalography (EEG), which are FDA-approved, noninvasive devices that measure electrical activity from the retina and brain using sensors placed on the skin around the eyes and scalp. Participants with Parkinson's disease will be tested before and after taking their prescribed Parkinson's medication (e.g., Sinemet® \\[carbidopa\u002Flevodopa\\]). Participants without Parkinson's disease will receive a single dose of compounded levodopa\u002Fcarbidopa eye drops (an FDA-approved drug used in an unapproved ophthalmic formulation) in one eye and a placebo eye drop in the other eye. The placebo consists of the same vehicle solution without levodopa\u002Fcarbidopa and contains 0.1% ascorbic acid, 0.001% benzalkonium chloride, and phosphate-buffered saline. Randomization will be used to determine which eye receives the levodopa\u002Fcarbidopa eye drop and which eye receives the placebo. Researchers will compare measurements obtained before and after treatment to evaluate whether blue-light visual responses are associated with dopamine activity.",[209,34],"Parkinson Disease",[211,212,213,214,215,216],"dopamine","retina","biomarker","brain","electroretinography","blue light","2026-08-10",{"date":219,"type":47},"2026-08-12",{"date":221,"type":24},"2026-10-01",{"date":223,"type":24},"2027-09-30",{"name":225,"class":54},"University of South Florida",{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":18,"sex":19,"minAge":63,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":25,"phases":236,"briefSummary":237,"conditions":238,"keywords":239,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":55},"100631253","location--and-frequency-dependent-effects-of-thalamic-temporal-interference-stimulation-during-sleep-100631253","NCT07498270","Location- and Frequency-Dependent Effects of Thalamic Temporal Interference Stimulation During Sleep","CAP-TI","Inclusion Criteria:\n\n* Medically healthy (based on self-report and study team review)\n* U.S. citizen or holding permanent resident status\n* English-speaking (able to provide consent and complete questionnaires)\n\nExclusion Criteria:\n\n* Any current or past history of neurological disorders or acquired neurological disease (e.g. stroke, traumatic brain injury), including intracranial lesions (including clinically significant findings identified in first MRI)\n* History of inpatient psychiatric hospitalization\n* History of head trauma resulting in prolonged loss of consciousness; or a history of greater than 3 grade I concussions\n* Current history of poorly controlled headaches including intractable or poorly controlled migraines\n* Any systemic illness or unstable medical condition that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.)\n* History of seizures, diagnosis of epilepsy, history of abnormal (epileptiform) EEG, or family history of treatment resistant epilepsy except for a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist\n* Possible pregnancy or plan to become pregnant in the next 6 months (self reported)\n* Any metal in the head\n* Any medical devices or implants (i.e. cardiac pacemaker, medication infusion pump, cochlear implant, vagal nerve stimulator)\n* Dental implants\n* Permanent retainers\n* Any hair braid, dreadlocks, hair pieces, or extensions which cannot be taken out before the study sessions\n* Any head coverings or headdress that participant feels uncomfortable removing for the purposes of study sessions\n* Any medication that may alter seizure threshold taken during the study i.e., ADHD stimulants (Adderall, amphetamine); Tricyclic\u002Fatypical antidepressants (amitriptyline, doxepine, imipramine, maprotiline, nortriptyline, bupropion); SSRIs (Escitalopram, Fluoxetine, Sertraline); Antipsychotics (chlorpromazine, clozapine), Bronchodilators (theophylline, aminophylline); Antibiotics (fluoroquinolones, imipenem, penicillin, cephalosporins, metronidazole, isoniazid); Antivirals (valacyclovir, ritonavir); OTC antihistamines (diphenhydramine, Benadryl)\n* Claustrophobia (a fear of small or closed places)\n* Back problems that would prevent lying flat for up to two hours\n* Regular night-shift work (second or third shift)\n* Sleep apnea or other sleep disorder (self-reported)","40 Years",{"count":235,"type":24},24,[27],"This study is to find out whether a type of non-invasive electrical brain stimulation called temporal interference transcranial electrical stimulation (TI-TES) can temporarily change brain activity during sleep, especially sleep spindles (brain rhythms in the \\~8-16 Hz range). Up to 24 healthy participants in Dane County, Wisconsin will be enrolled for 3 overnight study visits. Participants can expect to be on study for approximately 5 weeks, depending on scheduling availability.",[34,30],[240,241,242,243,244,245,246,247],"sleep","spindles","non-rapid eye movement","SSD","neurobiology","impairment","brain stimulation","non-invasive stimulation","2026-08-06",{"date":217,"type":47},{"date":251,"type":47},"2026-06-05",{"date":253,"type":24},"2028-02",{"name":255,"class":54},"University of Wisconsin, Madison",{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":18,"sex":19,"minAge":63,"maxAge":263,"enrollmentInfo":264,"targetDuration":4,"studyType":25,"phases":266,"briefSummary":267,"conditions":268,"keywords":269,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":278,"leadSponsor":280,"locationsCount":4},"100650757","probiotic-research-for-mental-health-in-adult-volunteers-100650757","NCT07751614","Probiotic Research for Mental Health in Adult Volunteers","A Randomized, Placebo-Controlled Pilot Study Evaluating a Probiotic Intervention for Mental Health","Inclusion Criteria:\n\n* 18-30 years of age\n* Native-level Danish language skills\n* No current psychiatric illness, confirmed with the Presence State Examination (PSE) and the Standardized Assessment of Personality (SAPAS)\n* No previous history of severe psychiatric illness, including bipolar disorder, recurrent unipolar depression, psychosis spectrum disorders, personality disorders, autism spectrum disorders, or attention deficit (hyperactivity) disorder (ADHD\u002FADD), confirmed with PSE and SAPAS. Participants may still be included if they have a history of a single depressive episode, or have experienced symptoms of anxiety, stress, or burnout more than 6 months ago.\n\nExclusion Criteria:\n\n* Recent use of probiotics (within the past 4 weeks)\n* Use of antibiotics within the past 3 months\n* Smoking, chewable tobacco, vaping, or use of other nicotine products\n* Neurological disorders (including dementia)\n* Use of psychotropic medication within the previous 6 months, including:\n* Anxiolytics\n* Antidepressants\n* Antipsychotics\n* Anticonvulsants\n* Centrally acting corticosteroids\n* Opioid pain relievers\n* Hypnotics\n* Prescribed sleep medications or herbal sleep aids (e.g., valerian)\n* Dyslexia\n* Severe physical illness, including:\n* Cardiovascular disease\n* Diabetes\n* Gastrointestinal pathology (e.g., colon cancer, colitis, Crohn's disease)\n* Gynecological pathology (e.g., endometriosis)\n* Urologic pathology (e.g., prostate cancer)\n* Severely immunocompromised status, including:\n* HIV positive\n* Being a transplant recipient\n* Use of anti-rejection medication\n* Use of steroids for more than 30 days\n* Chemotherapy or radiotherapy within the last year\n* Current alcohol or substance abuse disorder\n* Previous severe head trauma\n* History of epilepsy\n* Pregnancy or breastfeeding\n* Known allergy to any component of the test product\n* Participation in a clinical study with another investigational product within 60 days before screening, or plans to participate in another study during the study period\n* Significant change in dietary habits within the previous 4 weeks (e.g., starting a fibre-enriched diet)\n* Planned major changes in diet or exercise habits during the study period\n* Current pregnancy","30 Years",{"count":265,"type":24},60,[27],"This randomized, double-blind, placebo-controlled pilot study will evaluate the effects of four weeks of supplementation with a probiotic on mental health in healthy adults aged 18-30 years. Participants will be randomized to receive either probiotic or placebo and will complete study assessments at baseline and end of intervention, and will complete a range of behavioral, physiological, and questionnaire-based assessments before and after the intervention. The primary objective is to assess the effect on emotional reactivity measured in a virtual reality scenario at the end of the intervention. This exploratory study is intended to generate data to inform future clinical research.",[34],[270,271,272,273],"Gut microbiome","Mental well-being","Probiotic","Healthy adults","2026-08-05",{"date":276,"type":47},"2026-08-07",{"date":85,"type":24},{"date":279,"type":24},"2027-03-31",{"name":281,"class":54},"Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital",{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":18,"sex":19,"minAge":63,"maxAge":289,"enrollmentInfo":290,"targetDuration":4,"studyType":25,"phases":292,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":55},"100649091","phase-1-safety-tolerability-and-pharmacokinetic-evaluation-of-adb116-for-injection-100649091","NCT07729839","Safety, Tolerability, and Pharmacokinetic Evaluation of ADB116 for Injection","Study of Safety, Tolerability, and Pharmacokinetics of ADB116 for Injection in Healthy Chinese Adults: A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Phase I Clinical Trial","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form (ICF) prior to any study procedures and be able to comply with the protocol requirements.\n2. Aged between 18 and 45 years (inclusive of 18 years up to but not including 46 years) at the time of signing the ICF, male or female.\n3. At screening, male subjects must weigh ≥50.0 kg, female subjects must weigh ≥45.0 kg, and body mass index (BMI) = weight (kg) \u002F height² (m²) must be within the range of 19.0-26.0 kg\u002Fm² (inclusive).\n4. No history of major medical or surgical diseases prior to screening, and results of vital signs, physical examination, 12-lead ECG, laboratory tests, fundoscopic examination, chest X-ray, and abdominal ultrasound during the screening period must be normal or, if slightly outside the normal reference range, considered clinically insignificant by the investigator.","45 Years",{"count":291,"type":24},34,[68],"A Phase I Study of ADB116 for Injection in Healthy Chinese Adults. This study aims as follows:\n\nPrimary Objective:\n\n• To evaluate the safety and tolerability of a single intravenous bolus dose of ADB116 for injection in healthy Chinese adults.\n\nSecondary Objective:\n\n• To evaluate the pharmacokinetic (PK) profile of a single intravenous bolus dose of ADB116 for injection.",[34],"2026-08-03",{"date":274,"type":47},{"date":298,"type":47},"2026-05-31",{"date":300,"type":24},"2027-03-18",{"name":302,"class":117},"Jiangsu Aidea Pharmaceutical Group Co., Ltd.",{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":18,"sex":19,"minAge":233,"maxAge":21,"enrollmentInfo":311,"targetDuration":4,"studyType":25,"phases":313,"briefSummary":314,"conditions":315,"keywords":318,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":333,"locationsCount":55},"100638239","dora---a-study-using-digital-health-toolsplatform-to-explore-the-impact-of-the-consumption-of-senior-milk-powder-containing-synbiotics-on-the-gut-microbiome-in-healthy-aging-individuals-100638239","NCT07575529","DORA - A Study Using Digital Health Tools\u002FPlatform to Explore the Impact of the Consumption of Senior Milk Powder Containing Synbiotics on the Gut micRobiome in Healthy Aging Individuals","DORA - An Exploratory, Interventional Study Using Digital Health Tools and OneBiome to Explore the Impact of the Consumption of Senior Milk Powder Containing Synbiotics on the Gut micRobiome in Healthy Aging Individuals","DORA","Inclusion Criteria:\n\n1. Participants aged between 40 to 65 years (bounds included)\n2. Participants who are community-living\n3. Participants who are in good health (self-reported)\n4. Participants own and are willing to use their personal non-shared mobile device (iPhone 8 or later, with iOS version 16 or later), to pair with the study-provided Apple Watch SE, for the duration of the study\n5. Participant should be able to use mobile applications on smartphones to perform tasks in the study, have access to the internet and a smartphone or tablet to take and upload images and\u002For videos of stool, and other anatomical sites\n6. Participant should be able to comprehend the content of the study and to complete the study questionnaires in English\n7. Written and signed consent from participant\n8. Currently reside in Singapore and with the intention to reside in Singapore for at least the duration of the study.\n\nNote: Clinical trial participants may be permitted to undertake short-duration travel not exceeding 72 consecutive hours each time, provided such travel does not conflict with scheduled study visits, investigational product administration, or protocol-defined assessments. Prior notification to principal investigator or designated study personnel is required. The participant must be instructed on potential risks, adverse event reporting during the travel period.\n\nExclusion Criteria:\n\n1. Pregnant or lactating, or wish to become pregnant during the period of the study (self-reported)\n2. Participant with current or intended participation in a clinical study involving investigational or marketed products\n3. Use of named prebiotics, probiotics or synbiotics (in a capsule or sachet) within the last 4 weeks prior to screening or are planning to use it during the study including but not limited to the products listed below:\n\n   * BioGaia Probiotic Tablets\n   * LACTO FIT Probiotics\n   * Nano Singapore Digestive Wellness Formula\n   * California Gold Nutrition LactoBif Probiotics\n   * Life Space Probiotic\n   * Vivomixx 112.5 Billion Live Probiotics\n   * Duolac Daily Vitality Probiotic\n   * ATOMY Probiotics 10+\n   * Blackmores Ultra Max Probiotics+\n   * Holistic Way High Strength Probiotic 75 Billion\n4. Use of any commercial healthy aging milk powder within the last 4 weeks prior to screening or are planning to use it during the study including but not limited to:\n\n   * Boost Optimum\n   * Enercal complete\n   * Anlene\n   * Ensure\n5. Use of systemic antibiotics within the last 8 weeks prior to screening\n6. Known allergy or intolerance to Galactooligosaccharides (GOS), lactose, probiotics, or any ingredient in the SP\n7. Gastrointestinal (GI) surgery within the last 6 months prior to screening\n8. BMI below 18.5 kg\u002Fm² or above 27.5 kg\u002Fm²\n9. Participants who are using insulin, or have poorly controlled diabetes (HbA1c ≥ 10%) within last 3 months prior to screening\n10. Other severe disease(s) impairing activities of daily living or affecting the ability to complete the study assessments such as malignancy, end stage organ failure, COPD on long-term oxygen therapy, stroke with significantly residual functional weakness, cardiac failure with poor effort tolerance, significant neurological disease such as cognitive impairment from dementia, severe neuromuscular disease like Parkinson's disease, psychiatric disease\u002Fdisorder, auto-immune disease, allergic conditions requiring chronic systemic medication, other severe GI disease(s) such as Crohn's disease, GI cancer, or ulcerative colitis diagnosed by a physician\n11. History of drug abuse (Drug Abuse Screening Test (DAST) score of \\>2) or alcohol abuse (Alcohol Use Disorders Identification Test (AUDIT) score of \\> 7) within the last 6 months prior to screening\n12. Participants on a special diet, e.g., vegan, low-carbohydrate for intentional weight loss, ketogenic, low-FODMAP diet at the screening visit, or plan for such diet during the study duration\n13. Employees and\u002For children\u002Ffamily members or relatives of employees of Danone or the study team members (dependent relationship with study team members) participating sites such as, employees of the Investigator or of the Sponsor, members of the armed forces, and persons kept in detention\n14. Participant expected to be living in the same home as a current participating participant and to concomitantly receive SP",{"count":312,"type":24},100,[27],"The DORA study is a single-arm, open-label, interventional exploratory study designed to evaluate the impact of a synbiotic-containing senior milk powder on the gut microbiome and selected biological, physiological, and digital health parameters in community-living adults in good health.\n\nThe study enrolls adults aged 40 to 65 years and aims to investigate changes in gut microbial composition, with a primary focus on butyrate-producing microbial taxa, following at least 28 days of study product consumption. Secondary and exploratory objectives include assessment of stool metabolites, blood-based biomarkers, bowel patterns, sleep quality, physical activity, cognitive function, dietary patterns, and quality of life.\n\nApproximately 125 participants will be recruited in Singapore to achieve 100 study completers. Following informed consent and screening, participants undergo a baseline observation period of 14 days during which physiological and lifestyle data are collected using wearable digital health devices. Baseline assessments also include blood sampling, stool collection for microbiome analysis, digital imaging and videography, and completion of validated questionnaires.\n\nAfter completion of baseline assessments and collection of the first stool sample, participants initiate consumption of the study product, a senior milk powder containing a defined synbiotic formulation. The study product is consumed twice daily for a minimum of 28 days and up to 35 days to allow completion of study assessments.\n\nParticipants return for end-of-intervention assessments following the study product phase, including repeat biological sampling, physical and digital assessments, and questionnaires. Stool microbiome profiles and other exploratory outcomes are compared between baseline and post-intervention time points.\n\nThis exploratory study is intended to generate feasibility data and hypotheses regarding the effects of synbiotic nutritional intervention and the integration of biological and digital health data in the context of healthy aging.",[34,316,317],"Gut Microbiomes","AI",[319,320,321,322,323,324,325,326,327],"Healthy Aging","Gut Microbiome","Gut Health","Probiotics","Prebiotics","Nutritional Intervention","Microbiome Profiling","Digital Health","Wearable Devices","2026-07-31",{"date":295,"type":47},{"date":331,"type":47},"2026-04-27",{"date":279,"type":24},{"name":334,"class":117},"Danone Asia Pacific Holdings Pte, Ltd.",{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":18,"sex":19,"minAge":343,"maxAge":344,"enrollmentInfo":345,"targetDuration":4,"studyType":25,"phases":347,"briefSummary":348,"conditions":349,"keywords":352,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":55},"100643640","early-phase-1-test-retest-trial-with-11cmodag-005-in-pd-or-msa-and-amhc---pilot-phase-100643640","NCT07640542","Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot Phase","An Open-label, Single-center Study to Evaluate the Safety and Test-retest Characteristics of [11C]MODAG-005 as PET Radioligand for Imaging Pathological Alpha-synuclein Deposition in the Brains of Patients With Parkinson's Disease (PD) or Multiple System Atrophy (MSA) Compared to Age-matched Healthy Controls (AMHC) - Pilot Phase","PIOSA","Inclusion Criteria:\n\n* Key inclusion criteria: Patients with MSA fulfilling both the criteria for probable MSA (Gilman et al., 2008) and clinically established MSA (Wenning et al., 2022), patients with PD fulfilling the criteria for clinically established PD (Postuma et al., 2015) or age-matched healthy controls (AMHC).\n\nExclusion Criteria:\n\n1. Laboratory tests with clinically significant abnormalities and\u002For clinically significant unstable medical illness equivalent to CTC v5.0 (common toxicity criteria) toxicities greater than grade 2.\n2. Evidence of clinically significant disease that is expected to interfere with cognitive assessments or the ability to complete the trial procedures as judged by the investigator.\n3. Clinically significant renal and hepatic dysfunction as judged by the investigator.\n4. Known hypersensitivity to the active substance or to any of the excipients of \\[11C\\]MODAG-005 solution for injection.\n5. Known hypersensitivity to the active substance or to any of the excipients in anle138b (Emrusolmin) capsules.\n6. Participant has received an investigational drug within 3 months of screening.\n7. Blood donations within 7 days before enrolment.\n8. Pregnant (see 9.1.5) or breast-feeding or having the intention of getting pregnant. Female participants of childbearing potential and male participants with female partners of childbearing potential not willing to practice effective contraception during the trial period and for 90 days following each PET\u002FCT scan.\n9. Unsuitable veins for repeated venipuncture.\n10. Contraindication to blood sampling and\u002For arterial cannulation, including but not limited to allergy to local anesthetics, peripheral vascular disease, Raynaud's phenomenon as determined by abnormal Allen's test on both arms or abnormal coagulation profile at screening. If Allen's test should be \"abnormal\" on both arms, the participant will not be eligible for arterial sampling, but will participate in the remaining assessments.\n11. MRI exclusion criteria include but not limited to: findings of cerebrovascular disease (more than two lacunar infarcts, any territorial infarct \\>1 cm\\^3, or deep white matter abnormality corresponding to an overall Fazekas scale of 3 with at least one confluent hyperintense lesion on the Fluid-Attenuated Inversion Recov ery (FLAIR) sequence that is \\>20 mm in any dimension), infectious disease, space-occupying lesions normal pressure hydrocephalus or any other abnormalities associated with central nervous system (CNS) disease. Findings that are expected to be present in the PD and MSA participants (e.g. absence of swallow tail sign, presence of regional atrophy or hot cross bun sign) do not lead to exclusion of these participants.\n12. Implants such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips and other medical implants that have not been certified for MRI, or history of claustrophobia in MRI.\n13. Unwilling and\u002For unable to cooperate with trial procedures.\n\n    Exclusion criteria for age-matched healthy controls:\n14. Relevant hepatic parameters above upper limit of normal (ULN), i.e., glutamic pyruvic transaminase (GPT), glutamic oxaloacetic transaminase (GOT), bilirubin\n15. Relevant renal parameters outside normal limits, i.e., serum creatinine and blood urea nitrogen (BUN) above ULN; urinary albumin-creatinine ratio (uACR) below lower limit of normal (LLN)\n16. Systolic blood pressure \\\u003C90 or \\>140 mmHg; diastolic blood pressure \\\u003C45 or \\>90 mmHg; heart rate \\\u003C50 or \\>95 beats per minute (BPM)","50 Years","75 Years",{"count":346,"type":24},9,[128],"This is an open-label, single-center Phase 1 study evaluating the safety, tolerability, and test-retest characteristics of \\[11C\\]MODAG-005, an investigational positron emission tomography\u002Fcomputed tomography (PET\u002FCT) radioligand intended to image pathological alpha-synuclein deposition in the brain. The study will enroll participants with Parkinson's disease (PD), participants with multiple system atrophy (MSA), and age-matched healthy controls (AMHC).\n\nParticipants with PD or MSA will undergo two \\[11C\\]MODAG-005 PET\u002FCT imaging sessions: one baseline scan and one follow-up scan 7 to 48 days later. Age-matched healthy controls will undergo one baseline scan. A subset of PD and MSA participants will receive a single oral dose of anle138b (Emrusolmin) before the second scan to evaluate tracer uptake under blocking conditions. The primary objective is to assess the safety and tolerability of \\[11C\\]MODAG-005. Secondary objectives include evaluating whether \\[11C\\]MODAG-005 PET imaging can distinguish participants with MSA or PD from age-matched healthy controls, distinguish PD from MSA, and determine test-retest variability of PET outcome measures.",[350,351,34],"Parkinson Disease (PD)","MSA - Multiple System Atrophy",[353,354,355,356,357],"MODAG","MODAG GmbH","Synuclein","Neurodegeneration","Lewy Body","2026-07-30",{"date":328,"type":47},{"date":361,"type":47},"2026-07-29",{"date":363,"type":24},"2027-07",{"name":354,"class":117},{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":18,"sex":19,"minAge":63,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":25,"phases":375,"briefSummary":376,"conditions":377,"keywords":379,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":386,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":393},"100630142","phase-1-a-clinical-trial-to-test-the-safety-tolerability-and-how-the-body-processes-cpv-104-in-healthy-people-and-patients-with-c3-glomerulopathy-100630142","NCT07483827","A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy","A Phase 1 First-in-Human Clinical Trial in Healthy Participants and Patients With C3-Glomerulopathy to Assess Safety, Tolerability, and Pharmacokinetics of CPV-104","Essential One","Inclusion Criteria Healthy Volunteers (Part 1 - SAD-HV) :\n\n* Participants must be at least 18 years old and no more than 50 years old, at the time of consent, and must be able to sign and date the informed consent form (ICF) themselves.\n* Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. A participant with a clinical abnormality or laboratory parameter(s) not specifically listed in the exclusion criteria that is outside the reference range for the population being studied may be included only if the investigator, in consultation with the Medical Monitor, agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures or results.\n* Body weight within 50 kg for male\u002F 45 kg for female to 110 kg and BMI within the range 18 - 32 kg\u002Fm2 (inclusive).\n* Childbearing potential (CBP) participants should agree to use a highly effective method of contraception throughout the study and for 90 days after the last dose of the IMP.\n* CBP participants should agree not to donate oocytes or freeze for future use for the purposes of assisted reproduction during the study and for a period of 90 days after the last dose of the IMP. Male participants should agree not to donate sperm or freeze sperm for future use for the purposes of assisted reproduction during the study and for a period of 90 days after the last dose of the IMP.\n* CBP participants should have a negative pregnancy test at screening.\n* Participant provides written informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.\n\nExclusion Criteria Healthy Volunteers (Part 1 - SAD-HV) :\n\n* Participant has a history of clinically significant disorders or diseases affecting the endocrine, gastrointestinal, cardiovascular, hematological, liver, immune, kidney, respiratory, reproductive, or neurological systems (such as stroke or epilepsy). Participants with a history of minor medical issues may be considered for the study at the investigator's discretion.\n* Participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study.\n* Participant has a recent history of febrile illness or other evidence of a clinically significant active infection, within 14 days prior to screening.\n* Participant has a history of severe allergies (e.g. to medications, food, or latex) or has experienced an anaphylactic reaction to food or medicine.\n* Participant has a known hypersensitivity to any components of the IMP as stated in this protocol.\n* Alanine transaminase (ALT) or Aspartate aminotransferase (AST) \\>1.5 x upper limit of normal (ULN).\n* Total Bilirubin \\>1 x ULN, \\> 1.5 x ULN if Gilbert's syndrome.\n* Current or chronic history of liver disease or known hepatic or biliary abnormalities (except for Gilbert's syndrome or asymptomatic gallstones).\n* Participant has received any complement modifying treatment within 6 months prior to the first dosing day.\n* Exposure to more than four new chemical entities within 12 months prior to the first dosing day.\n* Participation in any other clinical study with a medical device or investigational medicinal product concurrently or within 5 half-life times or 3 months before the first dosing day (whichever is longer).\n* Presence of a QTc interval \\>450 ms for males or \\>460 ms for females, a history of risk factors for Torsades de Pointes (such as heart failure, cardiomyopathy, or a family history of long QT syndrome), uncorrected hypokalemia or hypomagnesemia, or concurrent use of medications known to prolong the QT\u002FQTc interval.\n* Participant is an employee of the sponsor or an employee or relative of the investigator.\n* Participant is unable to comply with the protocol (e.g. clinically relevant medical condition making implementation of the protocol difficult, unstable social situation, or otherwise unlikely to complete the study) or is, in the opinion of the investigator, otherwise unsuited for the study.\n* Participant has made a blood donation or blood products within 90 days prior to Baseline or plans to donate blood during the study.\n* Participant has an alcohol consumption of more than 21 units (males) or 14 units (females) of alcohol per week. One unit is equivalent to 8 g of alcohol: a half pint (240 mL) of beer, 1 glass (125 mL) of wine, or 1 (25 mL) measure of spirits).\n* Study participant has a high consumption of caffeine- or other xanthine-containing products (≥300 mg of caffeine- or xanthine-equivalent per day) (1 cup of coffee ≈ 100 mg of caffeine; 1 cup of tea ≈ 30 mg of caffeine; 1 glass of cola ≈ 20 mg of caffeine).\n\nInclusion Criteria C3G Patient (Part 2 - MAD-C3G):\n\n* Patient must be at least 18 years old, at the time of consent, and must be able to sign and date the informed consent form (ICF) themselves.\n* Patient must have a diagnosis of C3G confirmed by historical renal biopsy.\n* Patient must have proteinuria at screening.\n* Patient must have stable or worsening renal disease, be on stable and optimized symptomatic treatment, in the opinion of the PI, for at least 30 days prior to screening (treatments may include, but are not limited to, immunosuppressive agents, anti-hypertensives, steroids).\n* Body weight within 50 kg for male\u002F 45 kg for female to 110 kg and BMI within the range 18 - 32 kg\u002Fm2 (inclusive).\n* Childbearing potential (CBP) participants should agree to use a highly effective method of contraception, throughout the study and for 90 days after the last dose of the IMP.\n* CBP participants should agree not to donate oocytes or freeze for future use for the purposes of assisted reproduction during the study and for a period of 90 days after the last dose of the IMP. Male participants should agree not to donate sperm or freeze sperm for future use for the purposes of assisted reproduction during the study and for a period of 90 days after the last dose of the IMP.\n* CBP participants should have a negative pregnancy test at screening.\n* Participant provides written informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.\n\nExclusion Criteria C3G Patients (Part 2 - MAD-C3G) :\n\n* Patient has a history of clinically significant disorders or diseases affecting the endocrine, gastrointestinal, cardiovascular (including thromboembolic events like deep vein thrombosis, pulmonary embolism, known coagulopathy), hematological, liver, immune, kidney, respiratory, reproductive, or neurological systems (such as stroke or epilepsy). Participants with a history of minor medical issues may be considered for the study at the investigator's discretion.\n* Patient has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study.\n* Patient had a recent history of febrile illness or other evidence of a clinically significant active infection, within 14 days prior to screening.\n* Patient has a history of severe allergies (e.g. to medications, food, or latex) or has experienced an anaphylactic reaction to food or medicine.\n* Patient has a known hypersensitivity to any components of the IMP as stated in this protocol.\n* Patient had evidence of monoclonal gammopathy of unclear significance, infections, malignancy, autoimmune diseases, or other conditions to which C3G is secondary.\n* Patient with other renal diseases that would interfere with interpretation of the study.\n* Patient is receiving renal replacement therapy.\n* Patient is receiving or planned for receiving plasmapheresis.\n* Patient had a major organ transplant (e.g. heart, lung, kidney, liver) or hematopoietic stem cell\u002Fmarrow transplant.\n* Patient had a history or presence of any clinically relevant co-morbidities (e.g. advanced cardiac disease (NYHA class 4), severe pulmonary arterial hypertension (WHO class 4).\n* Alanine transaminase (ALT) or Aspartate aminotransferase (AST) \\>2 x upper limit of normal (ULN).\n* Total Bilirubin \\>1 x ULN, \\> 1.5 x ULN if Gilbert's syndrome.\n* Current or chronic history of liver disease, or known hepatic or biliary abnormalities (except for Gilbert's syndrome or asymptomatic gallstones).\n* Patient has received any complement modifying treatment within 6 months prior to the first dosing day.\n* Patient in any other clinical study with a medical device or investigational medicinal product concurrently or within 5 half-life times or 3 months before study start (whichever is longer).\n* Presence of a QTc interval \\>450 ms for males or \\>460 ms for females, a history of risk factors for Torsades de Pointes (such as heart failure, cardiomyopathy, or a family history of long QT syndrome), uncorrected hypokalemia or hypomagnesemia, or concurrent use of medications known to prolong the QT\u002FQTc interval.\n* Participant is an employee of the sponsor or an employee or relative of the investigator.\n* Participant is unable to comply with the protocol (e.g. clinically relevant medical condition making implementation of the protocol difficult, unstable social situation, or otherwise unlikely to complete the study) or is, in the opinion of the investigator, otherwise unsuited for the study.\n* Participant has made a blood donation or blood products within 90 days prior to Baseline or plans to donate blood during the study.\n* Participant has an alcohol consumption of more than 21 units (males) or 14 units (females) of alcohol per week. One unit is equivalent to 8 g of alcohol: a half pint (\\~240 mL) of beer, 1 glass (125 mL) of wine, or 1 (25 mL) measure of spirits).\n* Study participant has a high consumption of caffeine- or other xanthine-containing products (≥300 mg of caffeine- or xanthine-equivalent per day) (1 cup of coffee ≈ 100 mg of caffeine; 1 cup of tea ≈ 30 mg of caffeine; 1 glass of cola ≈ 20 mg of caffeine).",{"count":374,"type":24},39,[68],"This study is the first time the new medicine CPV-104 is being tested in people. CPV-104 is designed to regulate the complement system, which can be overactive in diseases such as C3 glomerulopathy (C3G), an ultra-rare kidney disorder.\n\nThe study includes healthy adults and adult patients with C3G to assess safety, tolerability, how the body processes the medicine, and whether the immune system reacts to it. The study is divided in two part; in Part 1 (SAD), healthy volunteers receive one IV dose of CPV-104 or a placebo while in Part 2 (MAD) patients with C3G receive four weekly IV doses of CPV-104 (no placebo).\n\nParticipants will have close monitoring, including side-effect checks, blood and urine tests, ECGs, vital signs, and blood samples to measure drug levels and antibodies. For those with C3G, researchers will also observe kidney function, although the main goal is safety, not testing effectiveness.\n\nA Safety Review Committee will regularly review results to ensure it is safe to continue to the next dose or study group.",[378,34],"C3 Glomerulopathy (C3G)",[380,381,382,383,384,385],"CPV-104","C3G","Complement System","kidney disease","kidney","Factor H",{"date":328,"type":47},{"date":388,"type":47},"2025-06-26",{"date":390,"type":24},"2026-11",{"name":392,"class":117},"eleva GmbH",17,{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":18,"sex":19,"minAge":63,"maxAge":401,"enrollmentInfo":402,"targetDuration":4,"studyType":25,"phases":404,"briefSummary":405,"conditions":406,"keywords":407,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":409,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":4},"100649923","phase-1-study-on-the-effect-of-famotidine-on-pharmacokinetics-of-taletrectinib-100649923","NCT07742384","Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib","An Open-label, Fixed Sequence Study to Evaluate the Effect of Famotidine on the Pharmacokinetics and Safety of Taletrectinib in Healthy Adult Participant","Inclusion Criteria:\n\n1. The participant must voluntarily sign an Informed Consent Form (ICF) prior to any study-related procedures.\n2. Participants are able to communicate well with Investigators and complete the study in accordance with the protocol.\n3. Between the ages of 18 and 55 years (inclusive) at the time of signing the ICF.\n4. Healthy adult participants (healthy refers to the status of no clinically relevant abnormalities identified through medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory examinations).\n5. Body weight is greater than 50.0 kg at Screening and the body mass index (BMI) is between 19 and 26 kg\u002Fm2.\n6. Males and\u002For females who meet any of the following criteria:\n\n   1. For males (irrespective of surgical sterilization \\[vasectomy\\]): agree to use effective contraception methods during the study intervention period and for at least 90 days after the last dose of study drug or agree with complete abstinence; and agree not to donate sperm during this same time period.\n   2. Females without menses for at least 1 year prior to Screening or documented to be surgically sterilized. Females of childbearing potential (FOCBP) must agree to use 2 concurrent highly effective methods of contraception or agree with complete abstinence from sexual intercourse from signing of the ICF until 45 days after the last dose of study drug. Usage of hormonotherapy for contraception should be recorded as well.\n7. For all females of childbearing potential, a negative pregnancy test must be obtained within 1 day before the first dose of study drug. Female participants of non-childbearing potential must meet at least 1 of the following criteria:\n\n   * Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; status may be confirmed with a serum follicle stimulating hormone (FSH) level confirming the postmenopausal state.\n   * Have undergone a documented hysterectomy and\u002For bilateral oophorectomy.\n   * Have medically confirmed ovarian failure. All other female participants (including female participants with tubal ligations) are considered to be of childbearing potential.\n8. Must agree to avoid strenuous exercise from 72 hours prior to dosing on Day 1 of Period 1 until the EOT\u002FET visit.\n9. Able to sign the informed consent and to comply with the protocol.\n10. Patients with adequate organ function meeting the following criteria:\n\n    1. Serum total bilirubin: ≤1×ULN.\n    2. Estimated creatinine clearance (CLcr) ≥90 mL\u002Fmin as calculated using the methodstandard for the institution (e.g., Cockcroft-Gault Equation).\n\nExclusion Criteria:\n\n1. Evidence or history of clinically significant hematology, kidney, endocrine, lung, gastrointestinal, cardiovascular, liver, mental, neurological, or allergic diseases (including drug allergies, but not including untreated, asymptomatic seasonal allergies at the time of dosing).\n2. According to the Investigator's judgment, there are clinically significant abnormal laboratory results (hematology, serum chemistry, coagulation, and urinalysis).\n3. Any active or unstable medical condition as judged by the Investigator.\n4. The Investigator believes that the participant may be at increased risk of eye disease or have a history of eye disease, such as glaucoma, retinal shedding, glass turbidity, moth disease,etc.\n5. Impaired cardiac function including clinically significant arrhythmias or clinically significant abnormality including but not limited to any of the following at Screening and Admission,repeat testing is allowed for verification, at the discretion of the Investigator:\n\n   1. Heart rate \\\u003C50 beats per minute (bpm) or \\>100 bpm (taken during supine blood pressure measurement).\n   2. Systolic blood pressure \\\u003C90 mmHg or ≥140 mmHg; diastolic blood pressure \\\u003C50 mmHg or ≥90 mmHg (supine blood pressure measurement).\n6. The 12-lead ECG shows that the QTc is \\>450 milliseconds (msec) or the QRS duration exceeds \\>120 msec. If the QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTc and QRS values should be used to determine the participant's eligibility.\n7. History of febrile illness within 5 days prior to the first dose of study drug.\n8. Positive blood screen for human Hepatitis B virus surface antigen, hepati is C virus antibody (HCV Ab), or human immunodeficiency virus (HIV) antibody.\n9. Pregnancy or lactation\u002Fbreastfeeding.\n10. Use of food or drugs that are known to be strong or moderate cytochrome P450 (CYP)3A4\u002F5 inhibitors or inducers or to be P-glycoprotein inhibitors within 14 days prior to the first dose of study drug until the EOT\u002FET visit.\n11. Consumption of Seville oranges or grapefruit-containing foods or beverages within 14 days prior to the first dose of study until the EOT\u002FET visit.\n12. Participants who have used prescription or over-the-counter (OTC) medication (other than ≤2 g\u002Fday acetaminophen or ≤800 mg\u002Fday ibuprofen or allowed contraception methods), vitamins, or herbal remedies, within 2 weeks or 5 half-lives before study drug administration, whichever is longer.\n13. Participants who have received live vaccines or attenuated vaccines within 28 days prior to the first dose of study drug until the EOT\u002FET visit.\n14. Participants who have received any investigational drug, device, biologic, or other agent (within 60 days or 5 half-lives, whichever is longer) prior to study drug administration on Day 1.\n15. Participants who are reluctant to stop consuming caffeinated or purine-containing foods (e.g., coffee, tea, cola, chocolate) from 72 hours prior to the first dose of study drug until the EOT\u002FET visit.\n16. History of regular alcohol consumption exceeding 14 drinks\u002Fweek (1 drink =12 ounces \\[360 mL\\] beer, or 5 ounces \\[150 mL\\] of wine, or 1.5 ounces \\[45 mL\\] of hard liquor), or participants who are unwilling to stop drinking alcohol from 72 hours prior to the first dose of study drug until the EOT\u002FET visit.\n17. Use of tobacco- or nicotine-containing products ≥5 cigarettes per day, or participants who are unwilling\u002Funable to stop tobacco- or nicotine-containing products from 72 hours prior to the first dose of study drug to the EOT\u002FET visit.\n18. A positive urine drug screen.\n19. A positive blood or breath test for alcohol.\n20. Underwent major surgery within 6 months prior to the first dose of study drug.\n21. Blood donation or blood loss within 3 months prior to the first dose of study drug of ≥400 mL.\n22. Plasma donation within 30 days prior to the first dose of study drug.\n23. Participants with gastrointestinal, liver, kidney disease, or other diseases known to interfere with drug absorption, distribution, metabolism, or excretion within 3 months prior to screening and during the Screening Period, or have a medical history of platelet reduction induced by heparin or heparin-induced thrombocytopenia.\n24. Unwilling or unable to comply with the dietary or other guidelines described in this protocol.\n25. Participants who are investigational site staff members directly involved in the conduct of the study or are their family members; site staff members otherwise supervised by the Investigator, or participants who are Nuvation Bio employees directly involved in the conduct of the study.\n26. Venous access considered inadequate for PK sample collection; history or evidence of adverse symptoms associated with phlebotomy or blood donation.\n27. The Investigator judges that the participant is not suitable to participate in the study.","55 Years",{"count":403,"type":24},56,[68],"This Phase 1 open-label trial aims to evaluate the effect of famotidine on the pharmacokinetics (PK), safety and tolerability of taletrectinib in healthy adult participants. To assess famotidine's impact on key PK parameters of taletrectinib and evaluate other PK parameters as well as safety endpoints.\n\nThe study design:\n\nPart 1: Taletrectinib 600 mg administered under 2-hour fasting condition with three regimens: (Treatment A: Taletrectinib alone, Treatment B: Taletrectinib 2 h after single 40 mg famotidine. Treatment C: Taletrectinib dosed between two 20 mg famotidine doses).\n\nPart 2: Taletrectinib 400 mg administered with standard low-fat meal, followed by either Treatment B or C of famotidine co-administration.",[34],[408],"Phase I",{"date":295,"type":47},{"date":411,"type":24},"2026-08-01",{"date":413,"type":24},"2027-02-02",{"name":415,"class":117},"Nuvation Bio Inc.",{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":18,"sex":19,"minAge":63,"maxAge":401,"enrollmentInfo":423,"targetDuration":4,"studyType":25,"phases":425,"briefSummary":426,"conditions":427,"keywords":428,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":55},"100643957","phase-1-a-phase-i-study-of-ns-079-in-healthy-participants-100643957","NCT07669571","A Phase I Study of NS-079 in Healthy Participants","A Phase I, Double-blind, Placebo-controlled Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of NS-079 in Healthy Participants","Inclusion Criteria\n\n1. Healthy males or females aged 18-55 years (inclusive), with a body mass index (BMI) between 18.00 and 32.00 kg\u002Fm2(inclusive) at screening.\n2. Not participated in any other clinical trials and received an investigational drug or device within the past 30 days or 5 half-lives prior to screening, whichever is longer.\n3. Women of non-childbearing potential (WONCBP) (as defined in Appendix 1); women of childbearing potential (WOCBP) who are abstinent from heterosexual intercourse as a preferred and usual lifestyle choice, or who agree to use highly effective contraception (as defined in Appendix 1) in combination with a condom from the time of signing the informed consent form until at least 90 days after the last dose of investigational product, agree to refrain from ova donation during this period, and return a negative pregnancy test at screening and baseline (Day -1).\n4. Surgically sterile males (with verbal confirmation of the absence of sperm in the ejaculate); males who are abstinent from heterosexual intercourse as a preferred and usual lifestyle choice, or who agree to use highly effective contraception with a female partner (as defined in Appendix 1) in combination with a condom from the time of signing the informed consent form until at least 90 days after the last dose of investigational product, and agree to refrain from sperm donation during this period.\n5. In good health, determined by the investigator\u002Fdelegate on the basis of medical history, physical examinations, vital signs, electrocardiograms (ECGs), clinical laboratory tests (hematology, coagulation, urinalysis, blood biochemistry). Repeated examination is allowed once per timepoint at the investigator\u002Fdelegate's discretion.\n6. Full understanding of the purpose, nature, procedures of the study, and the potential adverse reactions. Participant voluntarily participates and signs the informed consent form before any study procedures begin.\n7. Agree to provide a biological sample (blood or saliva\u002Fbuccal swab, per site capability) for Cytochrome P450 2D6 (CYP2D6) pharmacogenetic genotyping during the screening period, and the genotyping results must be available prior to randomization and dosing.\n8. Participants must be confirmed CYP2D6 Normal Metabolizers (NM) or Intermediate Metabolizers (IM) based on pharmacogenetic genotyping. For Part 3 \\[DDI\\] participants only: Must have a confirmed CYP2D6 NM status based on pharmacogenetic genotyping.\n\nExclusion Criteria\n\n1. Known hypersensitivity or allergy to the investigational product, its excipients, or any of its components, or a history of clinically significant allergic reactions that, in the opinion of the investigator\u002Fdelegate, may place the participant at increased risk.\n2. Known hypersensitivity to or severe intolerance of paroxetine or any SSRI (including serotonin syndrome or discontinuation syndrome) (for Part 3 \\[DDI\\] only).\n3. Unable to refrain from all known CYP2D6 substrate medications (including over-the-counter (OTC) medications such as dextromethorphan-containing cough and cold preparations) during paroxetine dosing (for Part 3 \\[DDI\\] only). Final clinical judgment on individual concomitant medications remains with the investigator\u002Fdelegate.\n4. Individuals with a history of intolerance to venipuncture or venous catheterization (e.g., recurrent syncope during blood draws or significant needle phobia) that, in the opinion of the investigator\u002Fdelegate, may interfere with the study procedures.\n5. Positive serologic test results for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (Anti-HCV) or human immunodeficiency virus antibody (Anti-HIV) at Screening.\n6. Average daily smoking of more than 5 cigarettes per day in the 3 months prior to Screening, or inability or unwillingness to abstain from the use of tobacco or nicotine-containing products (including cigarettes, e-cigarettes, vaping products, and nicotine replacement products) from 48 hours prior to the first dose through completion of the final safety follow-up visit.\n7. Excessive alcohol consumption, defined as average weekly alcohol intake exceeding 14 units during the 4 weeks prior to Screening (1 unit ≈10 g of pure alcohol; 1 alcohol unit is equal to 375ml 3.5% beer, 100 mL of wine, or 30 mL of 40% spirit), unwillingness or inability to abstain from alcohol and alcohol-containing products from 48 hours prior to the first dose through the completion of the final safety follow-up visit, or a positive alcohol breath test at Screening or upon admission to the clinical unit. (A repeat test may be performed once per timepoint at the investigator\u002Fdelegate's discretion).\n8. Excessive consumption of caffeinated beverages (e.g., coffee, tea, energy drinks), defined as an average of \\>8 cups\u002Fday (1 cup ≈ 250 mL) within 3 months prior to screening, or unwillingness or inability to refrain from caffeinated beverages from 48 hours prior to the first dose through the end of the inpatient confinement phase.\n9. Unwillingness or inability to abstain from grapefruit or grapefruit containing products, Seville (bitter) oranges, or pomelo\u002Fpomelo-containing products from 7 days prior to the first dose through the end of the inpatient confinement phase.\n10. Use of classic psychedelics or hallucinogenic substances with primary 5-HT2A agonist activity (e.g., lysergic acid diethylamide \\[LSD\\], psilocybin\u002Fmagic mushrooms, dimethyltryptamine \\[DMT\\], ayahuasca, mescaline) on 5 or more occasions lifetime, or any use within 5 years prior to Screening.\n11. Current or past substance use disorder (including alcohol or drugs of abuse) within the 12 months prior to Screening, as judged by the investigator\u002Fdelegate; use of ketamine or phencyclidine (PCP) for recreational or non-prescribed purposes within 12 months prior to Screening; use of cannabis within 6 weeks prior to Screening; use of other illicit drugs or non-prescribed psychoactive substances (including but not limited to MDMA, cocaine, opiates, amphetamines) within 4 weeks prior to Screening; or a positive drug of abuse urine screen at Screening or upon admission. Single or occasional use prior to the applicable washout period may be permitted at the investigator\u002Fdelegate's discretion, provided the urine drug screen is negative. A repeat drug screen may be performed once per timepoint at the investigator\u002Fdelegate's discretion.\n12. History or presence of the following conditions:\n\n    1. . Clinically significant (as judged by the investigator\u002Fdelegate) neurological or psychiatric disorders, defined as any of the following: history of epilepsy or any seizure disorder (excluding childhood febrile seizures); history of dementia or any clinically diagnosed cognitive disorder; clinically significant migraine, defined as: history of migraine with aura; chronic migraine (≥4 migraine days\u002Fmonth on average over the past 6 months); or use of prophylactic migraine medication or triptans within 30 days prior to first dose; any current or lifetime clinical diagnosis of schizophrenia spectrum or other psychotic disorder, bipolar I or II disorder, or borderline personality disorder; clinically significant depression, defined as: any current or lifetime clinical diagnosis of major depressive disorder or other depressive disorder; any history of pharmacological treatment for depression; any current clinical diagnosis of anxiety disorder or any history of pharmacological treatment for anxiety within 1 year prior to screening; or any history of psychiatric hospitalization. Neurological and psychiatric history will be assessed at Screening through clinical interview by the investigator\u002Fdelegate, supplemented by review of available medical records.\n    2. . Clinically significant (as judged by the investigator\u002Fdelegate) cardiovascular disorders, including history of prolonged QTc interval (defined as QTcF \\>450 ms for males or \\>470 ms for females, or any clinically significant ECG abnormality); or chronic cardiovascular diseases (specifically including history of cardiac valvulopathy or pulmonary hypertension or hypertension); or current hypertension (resting systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\>90 mmHg). Blood pressure assessment can be repeated at the discretion of the investigator\u002Fdelegate.\n    3. . Clinically significant (as judged by the investigator\u002Fdelegate) systemic diseases or conditions, including immunodeficiency or immunosuppressive disorders; malignant neoplastic diseases; or clinically significant endocrine, respiratory, hematologic (including coagulation), or digestive system diseases that may interfere with the safety of the participant or the interpretation of study results.\n    4. . Any of the following laboratory or medical history findings: AST or ALT \\>2 × ULN, or known or suspected Gilbert's Syndrome; eGFR \\\u003C60 ml\u002Fmin\u002F1.73m2; History of cholecystectomy.\n13. Family history of a psychotic disorder (including schizophrenia, schizoaffective disorder, or bipolar disorder) in a first-degree relative.\n14. Clinically significant (as judged by the investigator\u002Fdelegate) current or past suicidality based on the Columbia-Suicide Severity Rating Scale (C-SSRS), or psychiatric history indicating current suicidal ideation, or a history of active suicidal ideation or suicide attempts.\n15. Underwent major surgery within the past 6 months prior to the first dose (such as coronary artery bypass grafting, hepatectomy, gynecological surgery, etc.)\n16. Occurrence of acute neurological, digestive, respiratory, cardiovascular, endocrine, hematological, or other systemic diseases that may affect the absorption, distribution, metabolism, excretion, and safety evaluation of the investigational product within 3 months prior to screening judged by investigator\u002Fdelegate.\n17. Donation of blood or experienced blood loss ≥400 mL within the 3 months prior to the first dose; difficulties in venous blood collection; planned blood donation during the study or within 30 days after the study.\n18. Use of any prescription or non-prescription medications, including over-the-counter (OTC) medications within 14 days or 5 elimination half-lives (whichever is longer) prior to the first dose; use of any herbal products or nutritional\u002Fdietary supplements within 21 days prior to the first dose, except paracetamol (≤2 g per day); and use of any central nervous system acting drugs (including monoamine oxidase inhibitors \\[MAOIs\\], SSRIs), serotonergic supplements (e.g., St. John's Wort, 5-hydroxytryptophan \\[5-HTP\\], L-tryptophan), or strong\u002Fmoderate CYP2D6 inhibitor (e.g., bupropion, fluoxetine, paroxetine (prior use prohibited; protocol-directed administration as CYP2D6 index inhibitor in Part 3 \\[DDI\\] only), quinidine, terbinafine, duloxetine, cinacalcet) within 30 days or 5 elimination half-lives (whichever is longer) prior to the first dose. For Part 3 \\[DDI\\] only: Unwillingness or inability to abstain from NSAIDs (e.g., ibuprofen, naproxen, diclofenac) or aspirin throughout the paroxetine dosing and washout period; paracetamol (≤2 g\u002Fday) is the only permitted analgesic during this period.\n19. Receipt of vaccines within the 4 weeks prior to the first dose of the investigational product.\n20. Other factors deemed unsuitable for participation in the trial by the investigator\u002Fdelegate.",{"count":424,"type":24},78,[68],"The goal of this clinical trial is evaluate the safety, pharmacokinetics, and pharmacodynamics of NS-079 with its main metabolite (NS-079-M1) in healthy participants. The main questions it aims to answer are:\n\n* Is NS-079 safe and tolerable in heathy participants under tested dosing regimen?\n* What is the pharmacokinectic profile of NS-079 in healthy participants under tested dosing regimen and the effect of paroxetine? Researchers will compare NS-079 to a placebo to see the safety and tolerability when use NS-079.",[34],[429],"5-HT2A receptor",{"date":358,"type":47},{"date":432,"type":24},"2026-06",{"date":434,"type":24},"2027-05",{"name":436,"class":117},"NeuShen Therapeutics",{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":4,"eligibilityCriteria":443,"healthyVolunteers":18,"sex":19,"minAge":63,"maxAge":289,"enrollmentInfo":444,"targetDuration":4,"studyType":25,"phases":446,"briefSummary":447,"conditions":448,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":449,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":55},"100599208","phase-1-phase-1-study-of-adx-626-in-healthy-participants-100599208","NCT07081503","Phase 1 Study of ADX-626 in Healthy Participants","A Phase 1, Randomized, Blinded, Placebo-Controlled Study to Assess ADX-626 in Healthy Participants","Key Inclusion Criteria:\n\n* Age 18 to 45 years at the time of informed consent\n* Males or women of non-childbearing potential (WONCBP)\n* Willing to comply with all study requirements while participating\n* Suitable venous access for blood sampling.\n* Body weight ≥ 50 kg and a body mass index (BMI) ≤25 kg\u002Fm2\n* Normal laboratory results including liver enzymes, hemoglobin, platelet count, and coagulation parameters\n* Willing to use acceptable contraception methods if applicable\n\nKey Exclusion Criteria:\n\n* Significant medical condition such as hypertension, diabetes, cardiovascular disease, or cancer\n* History of bleeding or coagulation disorders, prior instances of major bleeding, or a family history of bleeding disorders.\n* Current infection\n* Participation in an interventional drug study within the last 90 days",{"count":445,"type":24},44,[68],"This first-in-human study will evaluate the safety and tolerability of ADX-626 in healthy participants. The study will also look at how ADX-626 interacts with the human body (the pharmacokinetics and pharmacodynamics of ADX-626).",[34],{"date":328,"type":47},{"date":451,"type":47},"2025-08-12",{"date":453,"type":24},"2027-01-22",{"name":455,"class":117},"ADARx Pharmaceuticals, Inc.",{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":18,"sex":19,"minAge":63,"maxAge":289,"enrollmentInfo":463,"targetDuration":4,"studyType":25,"phases":464,"briefSummary":465,"conditions":466,"keywords":469,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":478,"leadSponsor":480,"locationsCount":55},"100648930","the-effect-of-olive-leaf-extract-supplementation-on-training-induced-skeletal-muscle-functional-and-molecular-adaptations-in-healthy-volunteers-100648930","NCT07729072","The Effect of Olive Leaf Extract Supplementation on Training-induced Skeletal Muscle Functional and Molecular Adaptations in Healthy Volunteers","OLE_Training_1","Inclusion Criteria:\n\n1. Being between 18 and 45 years old\n2. Being healthy (assessed through the PAR-Q questionnaire).\n3. Being physically active, but not involved in any structured training program\n4. Being available for the study period.\n\nExclusion Criteria:\n\n1. If a participant answers positively to any YES\u002FNO question in the PAR-Q health questionnaire. For questions requiring a precision, any positive answer will be reviewed by a medical doctor, who will determine the inclusion\u002Fexclusion of the participant.\n2. Having allergy to xylocaine\n3. Being pregnant.",{"count":265,"type":24},[27],"The goal of this study is to investigate the effect of combining olive leaf extract supplementation with endurance training (moderate intensity continuous training or sprint interval training). We hypothesize that OLE supplementation during training, as compared to training alone with placebo, will translate into better performance outcomes. More specifically, we hypothesize that the additional benefits of OLE supplementation on performance will be mediated by improved mitochondrial characteristics in skeletal muscle and increased neural activation.",[34,467,468,324],"Exercise Training","Neuromuscular Adaptations",[470,471,472,473],"exercise","mitochondria","knee extensors","performance","2026-07-22",{"date":476,"type":47},"2026-07-27",{"date":85,"type":24},{"date":479,"type":24},"2029-12-31",{"name":481,"class":54},"University of Lausanne",{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":18,"sex":19,"minAge":63,"maxAge":489,"enrollmentInfo":490,"targetDuration":4,"studyType":25,"phases":492,"briefSummary":493,"conditions":494,"keywords":496,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":508,"leadSponsor":510,"locationsCount":55},"100627074","muvete-conciencia-exercise-and-mind-body-program-for-university-students-100627074","NCT07443904","Muévete conCiencia: Exercise and Mind-Body Program for University Students","Muévete conCiencia Project: Protocol for a Randomized Controlled Trial of Physical Exercise and Mind-Body Interventions in University Students","Inclusion Criteria:\n\n* Enrolled in a health-related undergraduate program at Universidad San Sebastián, Concepción campus (Chile).\n* Willing and able to attend scheduled intervention sessions and complete baseline and post-intervention assessments.\n* Provides written informed consent prior to participation.\n\nExclusion Criteria:\n\n* Diagnosis of neurological disease or severe psychiatric disorder that may interfere with participation or outcome validity.\n* Medical or musculoskeletal condition that contraindicates participation in moderate-to-vigorous physical exercise.\n* Regular participation in another structured exercise program during the study period or being a competitive athlete.","25 Years",{"count":491,"type":24},297,[27],"The goal of this clinical trial is to evaluate whether different physical exercise and mind-body interventions can improve executive functions and reduce stress in first-year university students.\n\nThe study focuses on healthy undergraduate students, men and women, aged approximately 18-25 years, enrolled in health-related programs at a Chilean university.\n\nThe main questions it aims to answer are:\n\nDo high-intensity dual-task physical exercise interventions improve executive functions (working memory, inhibitory control, and cognitive flexibility) and reduce stress in university students? Do mind-body exercise interventions (Tai Chi) reduce stress levels, measured through self-report and psychobiological biomarkers (cortisol)? Are there differential effects between high-intensity dual-task exercise, low-to-moderate intensity mind-body exercise, and cognitive training on executive functioning and stress-related outcomes?\n\nResearchers will compare:\n\n* high-intensity dual-task exercise group,\n* low-to-moderate intensity mind-body exercise group (Tai Chi), and\n* cognitive training group,\n\nTo determine whether physically integrated motor-cognitive training produces greater improvements in executive functions and stress biomarkers than mind-body exercise or cognitive stimulation alone.\n\nParticipants will:\n\nComplete baseline pre-intervention and post-intervention assessments, Neuropsychological tests of executive functions (working memory, inhibitory control, cognitive flexibility), Self-reported academic stress questionnaires, Psychobiological measures of stress (hair cortisol, salivary cortisol), Physical activity, anthropometric, and sociodemographic assessments.\n\nParticipate for 12 weeks (22 sessions, twice per week) in one of the following interventions:\n\nHigh-intensity dual-task physical exercise, combining aerobic, strength, and motor-cognitive tasks; Low-to-moderate intensity mind-body exercise (Tai Chi) emphasizing mindful movement, balance, breathing, and attentional control; Cognitive training sessions using a structured digital program. All sessions will be conducted in supervised, controlled settings by trained professionals, following standardized protocols to ensure safety, consistency, and adherence.",[495,34],"Healthy",[497,498,499,500,501,502,503,504],"executive function","stress","salivary cortisol","mind-body exercise","Dual-task training","Tai Chi","Cognitive training","university students",{"date":506,"type":47},"2026-07-24",{"date":161,"type":24},{"date":509,"type":24},"2027-04-30",{"name":511,"class":54},"Universidad San Sebastián",{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":4,"eligibilityCriteria":518,"healthyVolunteers":18,"sex":19,"minAge":63,"maxAge":21,"enrollmentInfo":519,"targetDuration":4,"studyType":25,"phases":521,"briefSummary":522,"conditions":523,"keywords":524,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":55},"100549124","phase-1-safety-tolerability-and-pharmacokinetics-study-of-l608-in-healthy-adults-100549124","NCT06429930","Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults","A Phase 1, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of L608 for Inhalation in Healthy Participants","Key Inclusion Criteria:\n\n1. Men and women aged between 18 and 65 (inclusive) at the time of Screening visit.\n2. Participants with Body Mass Index (BMI) of ≥18.5 and ≤32.0 kg\u002Fm2 and weight of at least 50 kg at Screening.\n3. Non-smokers or former smokers who have smoked ≤ 100 cigarettes in their lifetime and have not consumed any tobacco or tobacco-containing products for at least 3 months prior to Screening.\n4. Females must not be pregnant or lactating and must use acceptable, highly effective double contraception from Screening until 3 months after the last dose of the Investigational product.\n\nKey Exclusion Criteria:\n\n1. Participants with contraindications or sensitivity to any components of the study treatment.\n2. Participants with histories or active conditions of unexplained bleeding events, hemoptysis, abnormal bleeding tendencies, and\u002For coagulation disorders.\n3. Participants with histories or active conditions of asthma, sleep apnea, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, bronchiectasis, bronchospasm, and\u002For reactive airway. Subjects who have had childhood asthma which have resolved as deemed by the PI can be considered.\n4. Participants with histories or active conditions of myocardial infarction (MI), cerebrovascular accident (CVA), coronary artery disease (CAD), unstable angina, heart failure, significant cardiac arrhythmias, congenital or acquired valvular heart disease with clinically insignificant symptom, suspected lung congestion, and\u002For pulmonary arterial hypertension (PAH) causing by venous thromboembolism.\n5. Cohorts A1 and B1: Participants with systolic blood pressure \\\u003C 90 mmHg or \\> 140 mmHg and\u002For diastolic blood pressure \\\u003C 50 mmHg or \\> 95 mmHg at Screening or check-in visit.\n\n   Cohorts B2, B3, C1 and C2: Participants with systolic blood pressure \\\u003C 110 mmHg or \\> 140 mmHg and\u002For diastolic blood pressure \\\u003C 50 mmHg or \\> 95 mmHg at Screening, check-in visit or predose on Day1.\n6. Participants with FEV1 less than 80% predicted, FVC ˂ 80% predicted, or resting oxygen saturation less than 95% at Screening or check-in visit.\n7. Participants with histories of drug or alcohol abuse within 1 year prior to subject check-in (Day -1). Regular alcohol consumption defined as \\> 14 standard drinks per week for female and \\> 21 standard drinks per week for male.\n8. Consumption of products containing caffeine\u002Fmethylxanthines, poppy seeds and\u002For alcohol within 48 hours before dosing and products containing grapefruit and\u002For pomelo (shown to inhibit cytochrome P450 \\[CYP\\] 3A4 activity) within 10 days prior to drug administration, and\u002For participants unwilling to refrain from consumption of alcohol from 48 hours before dosing to Day 14.\n9. Receipt of blood products within 2 months prior to dosing.\n10. Positive results of human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and pregnancy test.\n11. Blood donation or significant blood loss (\\>480 ml) within 3 months prior to Screening.\n12. Participants unwilling to refrain from strenuous exercises from 7 days prior to dosing until the EOS visit.\n13. Participants planning to receive a tattoo, body piercing, or undergo any invasive procedure during the study period.",{"count":520,"type":24},40,[68],"This is a single ascending dose study of L608 in healthy participants and is being conducted to evaluate the safety of L608 with dose level ranging from 10 μg to 20 μg.",[34],[525,526,527,528,529],"Pulmonary Arterial Hypertension","Hypertension, Pulmonary","Lung Diseases","Respiratory Tract Diseases","Pharmaceutical Solutions","2026-07-21",{"date":474,"type":47},{"date":533,"type":47},"2025-04-11",{"date":535,"type":24},"2026-12-31",{"name":537,"class":117},"Pharmosa Biopharm Inc.",{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":4,"eligibilityCriteria":544,"healthyVolunteers":18,"sex":19,"minAge":63,"maxAge":4,"enrollmentInfo":545,"targetDuration":4,"studyType":25,"phases":547,"briefSummary":548,"conditions":549,"keywords":553,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":55},"100622802","a-usability-study-of-a-multi-channel-ecg-monitoring-device-100622802","NCT07388355","A Usability Study of a Multi-channel ECG Monitoring Device","WearLinq eWave Patch Study","Inclusion Criteria:\n\n* Adult \\>18 years old and able to consent\n* Capable of using a smartphone app\n* Willing to shave patch area if needed\n\nExclusion Criteria:\n\n* Planning to undergo an MRI during the study period\n* Known allergic reaction to adhesives or hydrogels or with family history of adhesive skin allergies, or any other dermatological conditional that could confound placement or results\n* Presence of pacemaker, ICD or other implanted electronic devices\n* Open wounds, lesions or infected or inflamed areas of skin at the placement site (left-center of chest\u002Fsternum)\n* Pregnant or intending to become pregnant during the course of the study",{"count":546,"type":24},500,[27],"This study it to evaluate the usability of the WearLinq eWave patch in a general adult population.",[34,550,551,552],"Heart Disease","Arrythmia","Cardiac",[554,555,556,557],"Electrocardiogram","ECG","EKG","Cardiac diagnostic","2026-07-19",{"date":530,"type":47},{"date":561,"type":47},"2026-07-06",{"date":563,"type":24},"2027-07-31",{"name":565,"class":117},"Wearlinq",{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":570,"acronym":4,"eligibilityCriteria":571,"healthyVolunteers":18,"sex":19,"minAge":63,"maxAge":64,"enrollmentInfo":572,"targetDuration":4,"studyType":25,"phases":573,"briefSummary":574,"conditions":575,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":55},"100647775","phase-1-a-pharmacokinetic-study-of-d-2570-in-participants-with-hepatic-impairment-and-normal-hepatic-function-100647775","NCT07715149","A Pharmacokinetic Study of D-2570 in Participants With Hepatic Impairment and Normal Hepatic Function","Inclusion Criteria:\n\n* Voluntarily participate in this study and sign the written informed consent form after full informed consent, and agree to comply with the procedures specified in the study protocol.\n* Aged 18 to 70 years.\n* Both males and females are eligible.\n* Male participants must weigh no less than 50 kg, and female participants must weigh no less than 45 kg.\n* Participants with normal hepatic function must have adequate hematologic, renal, and hepatic function.\n* Have no plan to reproduce or donate sperm\u002Feggs from screening until 30 days after the last dose of study drug, and agree to either completely abstain from sexual intercourse or use effective contraceptive measures from screening until 30 days after the last dose of study drug, as detailed in Appendix 3.\n\nExclusion Criteria:\n\n* Have undergone any prior surgery that may affect drug absorption, distribution, metabolism, or excretion, which, in the opinion of the investigator, would make the participant unsuitable for enrollment.\n* Are female and currently lactating, or have a positive serum pregnancy test result at screening or during the study period.\n* Have a known history of drug or substance abuse, or test positive for drugs of abuse on the urine drug screen.\n* Have participated in another interventional clinical trial within 3 months prior to screening, or are currently participating in another clinical trial (participants who withdraw from a prior trial before treatment, i.e., were not randomized or did not receive study intervention, may be enrolled in this study).\n* Have received a live vaccine within 2 months prior to study drug administration, or intend to receive a live vaccine during the study period.\n* Have any other condition or finding that, in the opinion of the investigator, would make the participant unsuitable for participation in this study.",{"count":235,"type":24},[68],"This is a single-center, non-randomized, open-label, parallel-group study. It will test D-2570 in people with liver problems and in people with healthy livers, to see how the drug moves through the body and whether it is safe.",[34,576],"Hepatic Impairment (HI)","2026-07-15",{"date":579,"type":47},"2026-07-20",{"date":581,"type":24},"2026-07-14",{"date":583,"type":24},"2026-11-30",{"name":585,"class":117},"InventisBio Co., Ltd",{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":4,"eligibilityCriteria":592,"healthyVolunteers":18,"sex":19,"minAge":63,"maxAge":401,"enrollmentInfo":593,"targetDuration":4,"studyType":25,"phases":595,"briefSummary":596,"conditions":597,"keywords":599,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":610,"locationsCount":55},"100646238","phase-1-a-study-of-gsm-779690t-in-healthy-adult-participants-100646238","NCT07690228","A Study of GSM-779690T in Healthy Adult Participants","A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacology of GSM-779690T in Healthy Adult Participants","Participants must meet all of the following inclusion criteria to be eligible for enrollment:\n\n1. Healthy and aged 18-55 years.\n2. Current Mini Mental State Examination (MMSE) score between 27 and 30 at screening.\n3. Able to provide their own written informed consent.\n4. Good general health with no disease expected to interfere with the study.\n5. Able to read, speak, and understand English to ensure compliance with cognitive testing and study visit procedures.\n6. Must be ambulatory and be willing to remain domiciled in the clinic for the required study procedures.\n7. Contraception requirements:\n\n   a. Women of childbearing potential (WOCBP) must agree to use a highly effective method of birth control (confirmed by the Investigator) from enrollment, throughout the study duration, and have a negative pregnancy test result at screening. Highly effective methods of birth control (those with a failure rate of \\\u003C 1% per year when used consistently and correctly) include: (i) Combined (oestrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal, (ii) Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, or implantable, (iii) Intrauterine device, (iv) Intrauterine hormone-releasing system, (v) Bilateral tubal occlusion, (vi) Tubal ligation, (vii) Sexual abstinence, i.e., refraining from heterosexual intercourse, or (viii) Vasectomized sexual partner (provided that partner is the sole sexual partner of the WOCBP study participant and that the vasectomized partner has received medical assessment of the surgical success).\n\n   b. Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) or who are postmenopausal.\n\n   c. Males with childbearing partners must be willing to practice sexual abstinence or use double-barrier protection during study treatment and until 1 week after the last dose of study treatment.\n\nParticipants who meet any of the following criteria must not be included in the study:\n\n1. A history of any current or clinically significant gastrointestinal, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardiovascular, endocrinological, ophthalmologic, hematological, or allergic disease or metabolic disorder.\n2. Use of any concomitant medications is prohibited, other than prescribed birth control methods stable 30 days prior to Day -1.\n3. A history of chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) or procedures that require intravenous contrast within 72 hours of study initiation.\n4. A history of a psychiatric disorder such as schizophrenia, bipolar disorder or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM).\n5. Any evidence of current suicidal ideation or any previous suicide attempt as evaluated by the Columbia-Suicide Severity Rating Scale (C-SSRS).\n6. Diagnosis of a neurodegenerative disease or dementia, including but not limited to Alzheimer's disease (AD), Parkinson's disease, and Huntington's disease.",{"count":594,"type":24},72,[68],"A Phase 1, single-centre, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single and multiple dose regimens of GSM-779690T in healthy adults. This first-in-human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GSM-779690T.",[34,598],"Alzheimer Disease",[600,601,602],"Pharmacokinetics","pharmacodynamics","single ascending dose","2026-07-08",{"date":605,"type":47},"2026-07-09",{"date":607,"type":24},"2026-08-15",{"date":609,"type":24},"2027-07-15",{"name":611,"class":117},"Acta Pharmaceuticals",{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":4,"eligibilityCriteria":618,"healthyVolunteers":18,"sex":19,"minAge":63,"maxAge":124,"enrollmentInfo":619,"targetDuration":4,"studyType":25,"phases":621,"briefSummary":622,"conditions":623,"keywords":4,"overallStatus":137,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":628,"leadSponsor":630,"locationsCount":55},"100646189","effect-of-the-ultrasound-guided-percutaneous-neuromodulation-on-the-mean-velocity-in-crossfit-practitioners-100646189","NCT07684534","Effect of the Ultrasound-guided Percutaneous Neuromodulation on the Mean Velocity in Crossfit Practitioners.","Effect of Ultrasound-guided Percutaneous Neuromodulation of the Transversus Abdominis on the Force-Velocity Profile During the Squat Performance in Crossfit Practitioners.","Inclusion Criteria:\n\n* Age between 18 and 60 years\n* At least 1 year of CrossFit training experience\n* Training frequency between 2 and 6 sessions per week\n\nExclusion Criteria:\n\n* Belonephobia (fear of needles)\n* Presence of cardiac conditions or implanted cardiac devices (e.g., pacemaker)\n* Pregnancy\n* Active oncological process\n* Skin conditions or lesions in the intervention area\n* Neurological or neurosensory disorders\n* Epilepsy\n* Current febrile condition\n* Recent use of antibiotics\n* Treatment with anticoagulant medication\n* Use of medications that may affect physical performance\n* Autoimmune diseases or use of immunosuppressive therapy\n* Active lumbar or abdominal pathology\n* Recent lumbar surgery or operations related to the intervention area\n* Active musculoskeletal injury or pain affecting squat technique or -performance\n* Undiagnosed pain affecting execution of the sporting movement.",{"count":620,"type":24},42,[27],"This randomized controlled blinded clinical trial aims to evaluate the effect of ultrasound-guided percutaneous neuromodulation (US-guided PNM) targeting the innervation of the transversus abdominis muscle on squat performance in CrossFit practitioners.\n\nThe transversus abdominis is a deep trunk muscle that contributes to lumbopelvic stability and force transmission during functional and athletic movements. Previous research suggests that improving neuromuscular activation of the trunk musculature may enhance movement efficiency and performance during resistance exercises. Ultrasound-guided percutaneous neuromodulation is a minimally invasive technique that applies electrical stimulation through a needle placed close to a peripheral nerve under ultrasound guidance, with the aim of modulating neuromuscular function.\n\nHealthy male and female CrossFit practitioners aged 18 to 60 years, with at least one year of training experience, will participate in the study. Participants will undergo an initial ultrasound assessment of transversus abdominis activation to classify and distribute the sample into groups. In a second session, mean velocity, mean propulsive velocity, and velocity loss during squat performance will be assessed using a linear velocity transducer. Participants will perform 3 sets of 2 repetitions of the squat exercise at 80% of their one-repetition maximum (1RM).\n\nFollowing baseline assessment, participants will be randomly assigned to either an experimental group receiving ultrasound-guided percutaneous neuromodulation of the iliohypogastric and ilioinguinal nerves, or a sham group receiving needle insertion without electrical stimulation. The intervention will consist of a TENS-type current applied at 10 Hz for 10 cycles of 10 seconds. Squat performance variables will be reassessed immediately after the intervention.\n\nThe purpose of this study is to determine whether US-guided percutaneous neuromodulation can acutely improve squat performance in trained CrossFit practitioners. The study hypothesis is that participants receiving active neuromodulation will demonstrate greater improvements in squat execution velocity and lower velocity loss compared with participants receiving the sham intervention.",[34,624],"Crossfit",{"date":626,"type":47},"2026-07-10",{"date":603,"type":47},{"date":629,"type":24},"2026-11-01",{"name":631,"class":54},"CEU San Pablo University",{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":636,"acronym":637,"eligibilityCriteria":638,"healthyVolunteers":18,"sex":19,"minAge":489,"maxAge":343,"enrollmentInfo":639,"targetDuration":4,"studyType":25,"phases":640,"briefSummary":641,"conditions":642,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":648,"completionDateStruct":649,"leadSponsor":651,"locationsCount":55},"100645164","postprandial-regulation-of-bone-perfusion-in-healthy-individuals-100645164","NCT07679516","Postprandial Regulation of Bone Perfusion in Healthy Individuals","GA-27","Inclusion Criteria:\n\n1. Age 25-50 years.\n2. BMI between 18.5-30 kg\u002Fm2.\n3. Normal gait.\n4. Premenopausal (if female).\n5. Informed consent.\n\nExclusion Criteria:\n\n1. Bone disease incl. confirmed osteopenia.\n2. Fracture within the last 6 months at the time of inclusion.\n3. Amputation or congenital defect of extremities.\n4. HbA1c\\>41.9 mmol\u002Fmol and\u002For diagnosed type 1 or type 2 diabetes.\n5. Any ongoing or prior medication that the investigator evaluates could interfere with the endpoints of the study (e.g. glucocorticoids or other medications that may compromise bone health).\n6. Pregnancy or breastfeeding (or plans thereof within the study duration).\n7. Not using effective hormonal contraceptives or an intra uterine device within study duration (e.g. oral contraceptives, transdermal patch, vaginal ring, Depo-Provera injections, Nexplanon implant).\n8. Ongoing or prior alcohol abuse (defined per ICD-10 classification for alcohol dependence syndrome, F10.21) or daily alcohol intake\n9. Use of any illicit substance or narcotics within three months of inclusion, including within study duration.\n10. Any physical or psychological condition that the investigator evaluates would interfere with trial participation.\n11. Recent (three months prior to inclusion), ongoing or planned weight loss within study duration (weight loss defined as exceeding -5% bodyweight, or intentional hypocaloric dieting)",{"count":66,"type":24},[27],"The goal of this clinical trial is to learn whether certain natural hormones - Glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-2, (GLP-2), and amylin - affect blood flow to the bones.",[34,643,644,645],"Bone Physiology","Bone Blood Flow Regulation","Peptide Hormones","2026-07-07",{"date":605,"type":47},{"date":558,"type":24},{"date":650,"type":24},"2028-05",{"name":652,"class":54},"University of Copenhagen",{"id":654,"slug":655,"hasResults":12,"nctId":656,"briefTitle":657,"officialTitle":658,"acronym":4,"eligibilityCriteria":659,"healthyVolunteers":18,"sex":19,"minAge":63,"maxAge":21,"enrollmentInfo":660,"targetDuration":4,"studyType":25,"phases":662,"briefSummary":663,"conditions":664,"keywords":665,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":672,"lastUpdatePostDateStruct":673,"startDateStruct":674,"completionDateStruct":676,"leadSponsor":678,"locationsCount":55},"100646605","phase-1-pharmacokinetics-and-safety-of-single-dose-wafermine-ketamine-sublingual-wafer-in-healthy-subjects-100646605","NCT07691372","Pharmacokinetics and Safety of Single-Dose Wafermine™ (Ketamine Sublingual Wafer) in Healthy Subjects","An Open-Label, Three-Period Crossover Study to Evaluate the Pharmacokinetics and Safety of Single-Dose Wafermine™ (Ketamine Sublingual Wafer) in Healthy Male and Female Subjects Under Fasting Conditions","Inclusion Criteria\n\n1. Clinically healthy participants (male and female) aged ≥ 18 to ≤ 65 years at the time of signing the informed consent.\n2. Research participants with no history of clinically significant cardiac, endocrine, gastrointestinal, hematological, hepatic, immunological, metabolic, urological, pulmonary, neurological, dermatological, or renal diseases or comorbidity of significance at the discretion of the Principal Investigator (or his\u002Fher delegate). The following medical history are permitted at the discretion of the Principal Investigator: history of childhood asthma; prior history of cholecystectomy; history of eczema with no use of steroid creams for 3 months prior to screening; history of fully resolved gestational diabetes; current or history of ADHD, anxiety or antidepression ( stable condition with no use of antidepressants 6 months prior to screening)\n3. Be able and willing to read, understand, sign, and date the Informed Consent Form prior to entering the study.\n4. Have adequate venous access for blood sampling.\n5. Female participants are eligible only if all the following contraceptive requirements are met:\n\n   These requirements also apply to ova donation.\n   * Women of non-childbearing potential (WONCBP) are not required to use contraception and are defined as women who meet at least one of the following criteria:\n\n     * Have undergone surgical sterilisation (e.g., hysterectomy, bilateral salpingectomy, or bilateral oophorectomy), or\n     * Are postmenopausal, defined as at least 12 consecutive months of amenorrhea without an alternative medical cause, with confirmation by follicle-stimulating hormone (FSH) levels at screening, where required.\n   * Women of childbearing potential (WOCBP) must agree to use highly effective methods of contraception, defined as methods with a failure rate of \\\u003C1% per year when used consistently and correctly, from screening until at least 33 days after the last administration of the investigational product.\n\n   Acceptable highly effective methods of contraception include:\n   * Combined (estrogen- and progestogen-containing) hormonal contraception (oral, intravaginal) associated with inhibition of ovulation\n   * Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable)\n   * Intrauterine device (IUD)\n   * Intrauterine hormone-releasing system (IUS)\n   * Bilateral tubal occlusion\n   * Sexual abstinence, provided this is the participant's usual and preferred lifestyle\n   * Not breastfeeding\n   * Be willing to complete all study procedures, safety laboratory tests, lifestyle considerations, restrictions, and other study procedures. Participants of childbearing potential will be eligible only if they have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day -1 of each study period, agree to avoid pregnancy for the duration of the study, and are not breastfeeding\n   * Male condom use is required in addition to hormonal contraception or other user-dependent methods, where applicable.\n\n   Unacceptable Contraceptive Methods (Do Not Meet Requirements)\n   * Condoms alone\n   * Double barrier method\n   * Female condoms\n   * Female diaphragms\n   * Dermal patches\n   * Withdrawal \u002F coitus interruptus\n   * Cycle tracking\n   * Periodic abstinence\n6. Male contraceptive Requirements These requirements also apply to sperm donation;\n\n   * Male participants must agree to use effective contraception or to remain abstinent (provided this is their usual and preferred lifestyle) from screening until at least 33 days after the last administration of the investigational product.\n   * Male participants must also agree not to donate sperm during this period.\n   * Surgically sterilized males are defined as:\n\n     * Bilateral orchidectomy: no contraceptive requirements .\n     * Bilateral vasectomy or documented azoospermia (≥90 days post-procedure): condom use is required only during intercourse with women of childbearing potential (WOCBP)\n   * For non-sterilized males, the following contraceptive requirements apply:\n\n     o Use of a male condom in combination with a highly effective method of contraception used by the female partner (WOCBP), as defined above\n   * The following are also considered acceptable:\n\n     * Same-sex relationships\u002Fintercourse only (no contraception required)\n     * Abstinence, provided this is the participant's usual and preferred lifestyle\n7. Body mass index between 18.5-30.0kg\u002Fm2 (inclusive) index.\n8. Deemed able to read and understand English in order to communicate with research staff and complete protocol required questionnaires and forms.\n\nExclusion Criteria\n\nMedical history\n\n1. Research participants with inflammatory or ulcerative disease in the oral cavity that may affect the absorption of the sublingual presentation.\n2. History of allergic reactions, anaphylactic reactions, severe systemic hypersensitivity, or any allergic reaction that, in the opinion of the Principal Investigator or his or her delegate, is likely to be exacerbated by the study drug.\n3. History of hypersensitivity to ketamine or any of the WafermineTM excipients.\n4. Elective procedures or surgeries scheduled after signing the Informed Consent Form and until the safety follow-up call \\[3 days ± 1 day after the 36.0-hour third period is taken\\].\n5. History of gastric bypass surgery\u002Fbariatric surgery or other gastrointestinal surgery or condition that may affect gastric emptying or absorption of the study drug.\n6. A history of 6 previous months of psychiatric disorders (schizophrenia, anxiety, acute psychosis, depression). A clinically significant history of psychiatric disorders (including but not limited to: schizophrenia, anxiety, acute psychosis, depression). Resolved psychiatric disorders (\\>6 months before screening) may be included at the discretion of the Investigator or delegate).\n\n   Risk of infection\n7. Positive serology for hepatitis C virus (HCV), hepatitis B virus (HBV) or human immunodeficiency virus (HIV).\n8. Presence of chronic, recurrent, or severe infection (e.g., pneumonia, sepsis) at the discretion of the Principal Investigator, within 90 days prior to the screening visit and between the screening visit and Day -1.\n9. Presence of symptoms of bacterial, fungal, or viral infection (including upper respiratory tract infection) within 14 days prior to the screening visit and between screening and Day -1. Participants with local fungal infection (e.g., candidiasis, ringworm, tinea pedis) are eligible for reevaluation after successful treatment of the infection.\n10. History of clinically significant condition involving the bladder or urinary tract, including frequent urinary tract infections (e.g. \\> 2 per year), or current symptoms of bladder irritation such as frequent or urgent need to urinate or burning with urination.\n11. Any immunization or vaccine administered within 30 days prior to Day 1. Laboratory assessment and results\n12. Abnormal and clinically significant results at the discretion of the Principal investigator (or his\u002Fher delegate) in the laboratory tests and electrocardiogram of the screening visit. Laboratory values out of range and determined to be not clinically significant at the discretion of the Principal Investigator or his\u002Fher delegate may be repeated on one occasion, the subject may be enrolled if the repeated value is within the normal range.\n13. Participants with aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin values ≥1.5 × upper limit of normal (ULN) at screening.\n\n    Pre-medicated and concomitant medications\n14. Participation in any other investigational study with drugs, biologics, medical devices, or treatment with an investigational product or therapy approved for investigational use within the 30 days prior to or 5 half-lives, whichever is greater, by Day -1.\n15. Use of any Over-The-Counter (OTC)\u002Fnon-prescribed drugs including vitamins, minerals, supplements or herbal medicines within 1 week of Period 1 study drug administration, or intake of prescribed drugs within 2 weeks of Period 1 study drug administration (or longer if the medication has a half-life long enough to potentially expose the healthy participant to any significant systemic exposure).\n\n    \\[Exception: hormone replacement therapy and oral contraceptives in female participants is allowed.\\]\n16. Use of drugs with enzyme-inducing properties (such as rifampicin and St John's Wort) or any drug known to be either a moderate or strong inhibitor of CYP3A4 or CYP2B6 within 3 weeks or 5 half-lives, whichever is greater, prior to treatment period 1 and throughout the study.\n\n    Others\n17. History of abuse or dependence on alcohol or illegal\u002Frecreational drugs during the development of the study.\n18. Positive results on the urine drug screen or breath alcohol test at screening and\u002For pre-dose. \\[Exception: a positive result on the urinary drug screen at screening only is allowed at the discretion of the Investigator provided the result can be reliably explained by recent medication and\u002For dietary history.\\]\n19. Current or recent use of tobacco or nicotine-containing products, defined as:\n\n    * Any smoking or nicotine use (cigarettes, e-cigarettes, vaping, chewing tobacco, etc.) within 30 days prior to screening, or\n    * History of regular (daily) smoking, or\n    * Casual\u002Fsocial smoking (\\>5 cigarettes or equivalent per week on average in the past 6-12 months)\n    * Participants with history of occasional smoking (≤5 cigarettes\u002Fweek) may be considered if they can commit to full abstinence during the entire study period including from screening through inpatient stays, and pass all other eligibility criteria (at the discretion of the Principal Investigator).\n20. Alcohol consumption 24 hours prior to Day -1.\n21. Habitual alcohol consumption \\> 14 units per week for men and \\> 10 units per week for women. One unit is equivalent to 250 mL of beer, 25 mL of hard liquor, or 125 mL of wine.\n22. Intake of beverages containing xanthines (coffee, tea, chocolate, cocoa, , cola) or charcoal-roasted foods 24 hours prior to Day -1.\n23. Habitual consumption of more than 4 caffeinated beverages in a period of 24 hours.\n24. Blood donation of one unit (approximately 450-500 mL) within the last 30 days prior to screening will be exclusionary.\n25. Strenuous physical exercise (e.g., heavy lifting, weight training, calisthenics, and aerobic exercise) within 48 hours prior to Day-1. Walking at a normal pace is allowed.\n26. Unwillingness or inability to comply with the requirements of the protocol.\n27. Other unspecified reasons that, at the discretion of the Principal Investigator or the Sponsor, determine that the subject is not suitable for inclusion.\n28. Participants who had been hospitalized in the 6 months prior to the screening visit.",{"count":661,"type":24},14,[68],"This is a Phase 1, open-label, three-period crossover study evaluating the pharmacokinetics and safety of single-dose Wafermine™ (ketamine sublingual wafer) at dose levels of 25 mg, 50 mg, and 75 mg in healthy adult participants under fasting conditions. Participants will receive all three dose levels in a fixed ascending sequence during a single inpatient admission, with washout periods between doses. Pharmacokinetic sampling will be conducted over 36 hours following each dose.",[34],[666,600,667,668,669,670,671],"Ketamine","Sublingual","Wafer","Phase 1","Healthy Volunteers","Wafermine","2026-07-02",{"date":603,"type":47},{"date":675,"type":24},"2026-06-09",{"date":677,"type":24},"2026-07-17",{"name":679,"class":54},"iX Biopharma Ltd."]